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ABSTRACT OF THE DISSERTATION
Contribution of LEDGF/p75 to prostate cancer chemoresistance
by
Melanie Mediavilla-Varela
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, June 2009
Dr. Carlos A. Casiano, Chairperson

Prostate cancer (PCa) is the second leading cause of male cancer death in the
United States, and is considered a health disparity because of its disproportionate
incidence and mortality in African American (AA) males. A major challenge in PCa
treatment is its recurrence into hormone refractory prostate cancer (HRPC). Docetaxel is
the standard of care for first line chemotherapy to HRPC. Unfortunately, most patients
ultimately manifest resistance to DTX and succumb to the disease. Circumventing DTX
resistance in HRPC will require better understanding of the mechanisms by which this
drug kills prostate tumor cells, and the genes that promote this resistance. We
investigated the mechanism underlying DTX-induced death and observed that it involved
the concomitant activation of caspase and lysosomal pathways. We also investigated the
role of the stress response protein and transcription co-activator lens epithelium derived
growth factor p75 (LEDGF/p75) in HRPC resistance to DTX. Our studies show that
LEDGF/p75 overexpression attenuates DTX-induced lysosomal destabilization and cell
death in a cellular model of HRPC, implicating this stress protein in DTX resistance in
vitro. However, LEDGF/p75 did not protect against cell death induced by the classical
apoptosis inducers TRAIL and staurosporine. This selectivity might be related to
LEDGF/p75’s ability to protect cells against insults that induce ROS generation, since we

xvn

observed that DTX but not TRAIL and staurosporine generated ROS. To better
understand the mechanism by which LEDGF/p75 confers its chemoresistant phenotype, a
protein expression profile was performed in PCa cells stably overexpressing LEDGF/p75.
A marked increase in the expression of the thiol-oxidoreductase ERp57 was observed in
overexpressing cells. Transactivation of ERp57 by LEDGF/p75 was confirmed using
transcription reporter assays, providing evidence that ERp57 might be a target gene of
LEDGF/p75. However, there was incomplete correlation in the expression patterns of
LEDGF/p75 and ERp57 in PCa cell lines and tissues. These findings suggest that
LEDGD/p75 might contribute to cellular resistance to drugs or insults that induce cell
death associated with ROS generation. If proven to contribute to DTX resistance in an in
vivo model, LEDGF/p75 and its target genes could be attractive targets for novel
therapeutic strategies in the treatment of HRPC.
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CHAPTER ONE
INTRODUCTION
The Prostate
The prostate is a gland that surrounds the urethra and contributes secretory
proteins to the seminal fluid. It is not required for viability or basal levels of fertility;
thus, its primary significance is its relevance for human disease (1). The prostate contains
three defined regions (Figure 1): the peripheral zone, the transition zone, and the central
zone (2,3). The significance of these zones comes from the fact that benign prostatic
hyperplasia (BPH) is found mainly in the transition zone, while most of the prostate
carcinomas are found in the peripheral zone (1).

Prostate Cancer
Statistics
Prostate cancer (PCa) is the most common male cancer and the second leading
cause of male cancer associated deaths in the United States. In 2008 it was estimated that
186,320 American men were diagnosed with PCa and 28,660 died because of the disease
(4). One in 6 men have a lifetime risk for being diagnosed with PCa and a 3.4% chance to
die because of this disease (5). The number of men with PCa increases dramatically as
the population of males over the age of 50 grows worldwide. Therefore, understanding
the causes that increase the risk of PCa has become an important epidemiological
concern. Epidemiological studies have lead to the identification of various risk factors

1
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Figure 1. Schematic illustration of the anatomy of the human prostate by Abate-Shen et
al. (1). In the illustration the three main regions of the prostate can be observed the
peripheral, transition and central zone.

3

that can increase susceptibility to PCa. These risk factors can be classified as endogenous
or exogenous, although there are some risk factors that fall in either category (i.e. race,
age, oxidative stress) (6).

PCa Risk Factors
Endogenous risk factors for PCa include family history, hormones, race, aging
and oxidative stress. These factors will be discussed below.

Family History
Hereditary factors account for a small percent (~10%) of PCa (1). Some of the
PCa susceptibility genes include the hereditary prostate cancer locus-1 (HPC1), the
hereditary prostate cancer locus-2 (HPC2 or ELAC2), Ribonuclease L (RNASEL),
macrophage-scavenger receptor 1 (MSR1), CHEK2, vitamin D receptor and paraoxonase
1 (PON1) (7-12). However, some investigators believe that there is detection bias since
individuals with family history of PCa are screened more aggressively (6).

Hormones
Endogenous hormones are required for the growth and maintenance of PCa.
Elevated levels of testosterone and its metabolite dihydrotestosterone have been
implicated in higher risk for PCa, even though some studies suggest an inconsistency
between this androgen and PCa risk (13-17). Furthermore, the largest randomized and
placebo controlled clinical trial, named the PCa Prevention Trial (PCPT), consisted of a 7
year intervention trial in which men were assigned to 5 mg of fmistrade, a selective
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inhibitor of the steroid 5a-reductase type 2, or placebo control. The steroid 5a-reductase
reduces testosterone into dihydroxytestosterone (DHT), estimated to be 10 times more
potnent than testosterone (18). The trial showed that the prevalence of PCa decreased by
25% in the fmistrade-treated arm, but that the number of high grade tumors increased
(19,20). To explain this difference the authors of the PCPT hypothesized that either
finasteride induced high grade PCa by reducing the intracellular levels of DHT within the
prostate or that finasteride selects high grade tumors by inhibiting low grade tumors (18).

Race
Disparities in the incidence and mortality of PCa patients with different racial
backgrounds have lead to the observation that African American (AA) men have one of
the highest reported incidence rates in the world, and their mortality is markedly higher
than that of white American (WA) men (21). AA men develop the disease 1.6 times more
frequently with a mortality rate of 2.5 times greater than their WA men counterparts of
the same age (22-24). In addition, SEER (Surveillance Epidemiology and End Results)
incidence statistics reported that while WA men had an incidence of 153 per 100,000
men, AA men incidence was 239.8 per 100,000 men (these rates are based on cases
diagnosed in 2002-2006 from 17 SEER geographic areas) (25). AA men are younger at
the time of diagnosis, tumors are higher in stage and grade, and have a shorter survival
rate when compared to WA men (26). Fowler et al. compared the outcomes of 39 WA
men and 524 AA men with PCa diagnosed between 1982 and 1992 and reported that
localized PCa was more lethal in AA men than in WA men (27).
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The reasons for these racial differences in PCa incidence and mortality are
multifactorial. Factors that have important roles in these disparities are socioeconomic
status, access to health care, genetic susceptibility and diet. Tewari et al. reported that
socioeconomic status related to half of the differences between AA and WA men (28).
Wallace et al. (29), using microarray analyses, compared the expression profile of
primary prostate tumors from 33 AA men and 36 WA men. They were able to identify
two genes that were upregulated in AA men when compared to WA men, PSPHL and
CRYBB2 (29). Little is known about the function of these two genes, and further studies
will be needed to confirm their importance in PCa disparities. It has also been reported
that AA men have higher levels of androgen metabolites as compared to WA men, such
as higher circulating levels of testosterone (30,31). In addition, PSA values at diagnosis
are greater in AA men compared to WA men (32,33). Furthermore, diet has been
implicated as a risk factor between different races. It is known that AA men have a diet
characterized by less fruit and vegetable consumption and higher fat intake, when
compared to other races, which may contribute to their higher risk (34). This was
confirmed when it was observed that Japanese men, which consume a relative low fat
diet, had lower PCa risk, but as the fat content of their diet increases towards Western
levels, the incidence has also increased (35).

Oxidative Stress and Aging
Oxidative stress and aging are considered risks for PCa since morphological
studies have shown a transition from proliferative inflammatory atrophy (PIA) to
adenocarcinomas, and an increase in the frequency of BPH, prostate intraepithelial
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neoplasia (PIN), and PCa as men become older (6,36-38). The prevalence of PCa by age
category is: 3% for men aged 60-64, 10% for men aged 70-74, 15% for men aged 80-84,
and 14% for men over 85 years old (5,39). These numbers are expected to increase due to
the fact that in 2030, 20% of the population will be 65 years or older, compared to 13%
today (40). Increasing evidence has indicated that oxidative stress is associated with
aging and cancer through an imbalance in cellular prooxidant-antioxidant status (41-43).
Young healthy individuals are equipped with adequate antioxidant defense mechanism to
protect against free radicals through ROS detoxification enzymes such as superoxide
dismutases (SODs) (42). In aging individuals, a decrease in detoxification enzyme
activities has been observed (43). Thus, progressive accumulation of DNA adducts and
increase in DNA strand-break frequency, due to ROS, are found in older men with an
increase in PCa risk (43-45).
Exogenous risk factors include: diet and environmental agents. These risk factors
will be discussed below.

Diet
A variety of dietary factors have been implicated in the development of PCa. One
of these factors is higher fat consumption, specifically polyunsaturated fat. Four case
control studies found a positive correlation between higher intake of polyunsaturated fat
and higher risk of PCa (46-49). It is still unknown how dietary fats increase the risk of
PCa although some groups have speculated that a higher fat intake leads to alterations in
the hormonal profile, increases oxidative stress, and generates fat metabolites that act as
protein or DNA-reactive intermediates (50-52). Block et al. reviewed 200 studies and
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found a statistically significant protective effect in diets high with fruits and vegetables in
128 out of 156 studies (53,54), suggesting that a high intake of fruits and vegetables
might be a valid tool for cancer prevention. Migrant studies have shown that Asian
American men living in the US have higher rates of PCa than their counterparts that live
in their native country (55,56). The physical inactivity and higher fat and meat intake of
westernization has been proposed to contribute to the increase in cancer risk (57). Other
dietary factors implicated with PCa risk are vitamin A, C, D, E, selenium and lycopene.
Studies suggest that there is a correlation between lower levels of these vitamins and
higher risk of PCa (48,58-62). This was confirmed in randomized double-blind trials
showing that a diet supplemented with selenium reduced the risk of PCa (63,64).

Environmental Agents
One class of environmental agents that have been linked to PCa are the endocrine
disruptive chemicals (EDC) (6). EDC’s alter hormonal activity either positively or
negatively via exposure through food or water consumption, or through inhalation.
Pesticides are also considered environmental agents that might increase the risk of PCa.
Studies in the Netherlands, Sweden and North Dakota linked higher exposure to
pesticides with a higher PCa incidence or risk (65-67). Alavanja et al. specifically linked
the use of chlorinated pesticides in men over 50 years old to a higher PCa risk (68).
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Screening and Diagnosis
Prostate-specific Antigen (PSA)
The discovery of PSA in the 1990s as a screening biomarker for PCa has had a
significant impact on early diagnosis, leading to an increase in the reported incidence of
PCa (69,70). PSA, also known as kallikrein 3, is a protease that belongs to the kallikrein
family, involved in the digestion of proteins in the seminal fluid (71-73). Currently, PSA
is used as the standard biomarker for diagnosis of PCa. Although most of the diagnosed
PCa cases are detected by monitoring rapid increases in the levels of PSA over a
relatively short period of time, this biomarker is not specific for PCa since it can also
indicate that the patient has a benign prostate condition such as BHP or prostatitis. In the
1990s a PSA value of 4 ng/mL was established as the cutoff to seek a prostate biopsy
(70). Although this value is still in use, it was recently recognized that patients with PSA
levels between 2.5 to 4 ng/mL had similar PCa risk as men with PSA levels higher than 4
ng/mL (74,75). Thompson et al. showed that an appreciable proportion of patients with
PSA levels less than 4 ng/mL had PCa detected with needle biopsy (76). Approximately
11% of men with PSA levels less than 2 ng/mL had high grade cancers. In addition, 21%
of the tumors detected at PSA level between 2 and 4 ng/mL were high grade. There is
concern about using a lower PSA threshold. First, it would increase the number of
negative biopsies performed (77). Second, it will result in the diagnosis and treatment of
many potentially indolent tumors (77). Even though the level of PSA is not completely
effective in the diagnosis of PCa, the World Health Organization (WHO), in 2004,
decided that PSA is still the best marker even though no specific cut-off point could be
defined (78).
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Biomarkers
The inadequacies found in PSA testing underscore the need for new PCa
biomarkers. Some promising biomarkers that might aid in the diagnosis of PCa are:
KLK2, KLK11, Hepsin, and TMPRSS2:EGR/ETV1 (70). KLK2, human kallikreinrelated peptidase 2, and KLK11, human kallirein-related peptidase 11, are secreted
proteases from the same family as PSA. Studies from patient sera have shown
improvements in PCa diagnosis when KLK2 and PSA; or KLK11 and PSA are used in
combination (79,80). Hepsin is a protease produced at high concentrations in prostate
tissue with 90% of PCa tumors showing overexpression of this protein (81). Lastly,
TMPRSS2:EGR and TMPRSS2/ETV1 are gene rearrangements that have been recently
implicated in PCa. In a cancer outlier profile analysis there was an 80% occurrence of
this rearrangement (82). These fusions were observed in 42% of PCa patients, 20% of
patients with PIN, and rarely in BHP patients (83). These are just a few examples of
possible biomarkers that might help, in combination with PSA, to diagnose PCa more
effectively.

Progression and Treatment
The progression from a normal prostate to PCa is illustrated in Figure 2. There is
consensus that the progression of this disease starts with PIN, leading to PCa and ending
in metastasis. In 1999, De Marzo et ah, proposed that a prostatic lesion called PIA is the
precursor of PIN (84).
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PIA
PIA contains focal areas of epithelial atrophy that fail to differentiate into
columnar secretory cells, which tends to occur in the periphery of the prostate, where
most PCa are found (Figure 2) (84-87). PIA has been associated with chronic
inflammation, arising as a consequence of the regenerative proliferation of prostate
epithelial cells in response to injury caused by inflammatory oxidants (84). Some
characteristics in the development of PIA from a normal prostate are the infiltration of
lymphocytes, macrophages, and neutrophils, which might be caused by repeated
infections, dietary factors, and/or the onset of autoimmunity (88). These phagocytes
release reactive oxygen and nitrogen species causing DNA damage, cell injury, and cell
death, thus triggering the onset of epithelial cell regeneration (88). An important event
associated with PIA is the loss or downregulation of p27 (88-92). p27 is a cyclin
dependent kinase inhibitor encoded by the gene CDKN1B. A functional role of p27 in
PCa has been suggested by targeted gene disruption, which resulted in hyperplasia of
prostate tissue (1). Following the atrophy caused by PIA, the cells undergo additional
genetic changes that lead to PIN.
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Figure 2. Schematic drawing of the progression of PCa by Nelson et al. (86). The normal
prostate has differentiated basal and columnar cells. As it progresses to PIA focal areas of
epithelial atrophy develop and, cells fail to differentiate into columnar secretory cells. In
PIN lesions disruption of the basal cell layer can be seen as well as nuclear abnormalities.
When it progresses to PCa the basal cell layer is lost as well as the distinct glandular
architecture. Cells appear dedifferentiated.
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PIN
PIN lesions are characterized by loss of basal cells and invasion of luminal cells
into the periphery (Figure 2) (93). One of the most important genetic changes in these
lesions is the loss of specific regions of chromosome 8p, which occur in as many as 80%
of prostate tumors (94,95). The loss of the 8p 12-21 region occurs in PIN lesions and early
invasive carcinomas (1). In this chromosomal region we find the homeobox gene
NKX3.1 (95-97). Evidence derived from mouse models showed that the loss or mutation
of NKX3.1 leads to PIN like lesions and defects in the prostate ductal morphogenesis
similar to the ones found in human PIN (1,98,99). PIN lesions can be classified into four
architectural types: tufting, micropapillary, cribiform, and flat (100-104). There is
evidence suggesting that high grade PIN is a preneoplastic lesion in PCa. This is
supported by the finding of PIN lesions in the peripheral zone, where PCa develops
(103). Second, the appearance of PIN lesions precedes that of the carcinoma by ten years
(105). Third, the chromosomal abnormalities found in PIN resemble those found in early
stages of PCa (106-109). Fourth, the architectural and cytological features of PIN
resemble those found in PCa (102). Lastly, markers of differentiation found in early PCa
are found in PIN lesions (104,106). If PIN and PCa have some similarities, the question is
how can they be differentiated? The main differences between them are that PIN lesions
have intact basement membrane and do not produce high levels of PSA when compared
to the initial stages of PCa (102,106).
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PCa
Normal prostate epithelial cells have a relatively low rate of proliferation. PIN
and localized PCa show a seven to ten fold increase in the rate of proliferation; therefore,
altered cell cycle control is likely to play a role in PCa (110). Also, localized PCa is
characterized by a continued proliferation of genetically unstable luminal cells and
accumulation of genomic changes (88). These genomic changes are observed in the loss
of regions of chromosomes lOq and 13q. The loss of chromosome lOq has been found in
approximately 50-80% of PCa, specifically loci 10q23.1 and 10q24-q25 (108,111-118).
A potential candidate gene for this region is PTEN/MMAC1. PTEN encodes a lipid
phosphatase with PIP-3 as its substrate (86). Loss of PTEN results in activation of
PKB/AKT kinase, leading to decreased sensitivity to cell death (1,119,120), Evidence
implicating PTEN as a key event in prostate carcinogenesis include the observations that
PTEN is mutated in four PCa cell lines and PTEN heterozygous mutant mice developed
prostatic epithelial hyperplasia and dysplasia (121-124). Loss of parts of chromosome
13q, including a region for the retinoblastoma (Rb) gene, occurs in 50% of prostate
tumors (125-127). Loss of Rb protein expression has been observed in localized as well
as in more advance stages of PCa (115,128,129).

Treatment of PCa
Localized PCa is the most commonly diagnosed stage in patients. The main
treatment for this stage is either radiation therapy or prostatectomy (93). The American
Urological Association has established guidelines for the treatment and/or management
of localized PCa. These are: 1) Low risk patients are given a radiation dose higher that 70
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Gy, which might decrease the risk of PSA recurrence; 2) Intermediate risk patients are
given a conventional dose of 70 Gy with the use of neoadjuvant and concurrent hormonal
therapy; and 3) High risk patients are given a combination of long term hormonal therapy
(V).
Unfortunately, PCa patients often relapse and aberrant prostate tumor growth is
observed after radiation therapy. The first sign of failure to treatment is usually a rapid
rising in the serum PSA levels (7). These patients are then subjected to androgen ablation
therapy through either chemical or surgical castration. Since the prostate cells are reliant
upon androgens for growth or survival, these cells generally die within a short period of
time (93). In most cases, such treatment ultimately results in the recurrence of highly
aggressive and metastatic PCa that is androgen independent, in which death occurs within
a few years in the majority of the cases (1,130). This stage is known as hormone
refractory prostate cancer (HRPC).

Hormone Refractory Prostate Cancer
Possible explanations on how HRPC arises include variable combinations of
clonal selection, adaptive upregulation of anti-apoptotic genes, ligand-independent
activation of the androgen receptor, and alternative growth factor pathways (131-139).

Treatment of HRPC
Chemotherapy agents used in the treatment of HRPC fall into three categories: 1)
intercalating agents, 2) alkylating compounds, and 3) microtubule stabilizing agents (93).
Intercalating agents include daunorubicin, doxorubicin and epirubicin. These agents
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intercalate between base pairs of DNA, create free radicals that initiate DNA damage,
and inhibit the nuclear enzyme topoisomerase II (140). Together, these events lead to the
demise of a cancer cell. One of the main alkylating agents used is estramustine, a stable
conjugate of estradiol and nitrogen mustard (141). The premise for the use of this drug
was based on the belief that the estradiol portion of the agent would facilitate uptake by
steroid receptors, whereas the nitrogen mustard would perform the alkylation. However,
new evidence suggests that estramustine inhibits microtubule function and affects
structural proteins within the nuclear matrix (142,143). Microtubule stabilizing agents are
used based on the central premise that behind all neoplasia there is an uncontrolled cell
division. Therefore, targeting the microtubules and preventing the process of mitosis and
cell division has become prominent in PCa treatment. Most microtubule stabilizing
agents are from the taxoid family. Taxanes have the capacity to bind to (I-tubulin that is
already incorporated in the microtubules preventing disassembly, stabilizing the mitotic
spindle, and triggering mitotic catastrophe and apoptosis (144-148). These pathways
include inactivation of bcl-2, activation of INK, Raf-1, and caspase dependent and
independent pathways (149,150). Of these three chemotherapeutic agents, only the
taxanes, specifically docetaxel, have shown an increase in the overall survival in patients
with HRPC (151,152).
Taxanes (docetaxel). Taxanes were discovered in 1967 by Wall and Wani, who
isolated them from the bark of the Pacific yew tree (153). The first taxane isolated was
called Taxus brevifolia or Taxol® (Figure 3), also given the chemical name paclitaxel.
Susan Horwitz
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Figure 3. Chemical structure of paclitaxel (Taxol®) and DTX (Taxotere®) as shown by
He et al. (154). The difference between paclitaxel and DTX can be observed in the side
chain that was esterified.
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and colleagues discovered its unique mechanism as a microtubule stabilizer in 1979
(155). Because of the limited resources available and the possible destruction of
millenary plants (Pacific yew), clinical development was slow despite the first
encouraging results. The search for alternate sources was encouraged and led to the
isolation of 10-deacetylbaccatin-III from the needle of the most common European yew
T.baccata, thus obtaining a renewable source for the drug. Since then, paclitaxel has been
approved by the FDA to treat ovarian, breast and non-small-lung cell carcinoma (156).
Since paclitaxel worked effectively in different kinds of cancer, the need of better and
new drugs led to the semisynthesis of paclitaxel to obtain better results in the clinical
trials. This was followed with the development of a second line taxane called docetaxel
(DTX) through the esterification of its precursor (Figure 3).
Docetaxel, or Taxotere®, exerts its cytotoxic activity by promoting and
stabilizing microtubule assembly of tubulin, thus blocking mitotic cell division in the M
phase. This leads to phosphorylation of Bcl-2, which inhibits its anti-apoptotic effect
(157). DTX binds to the intermediate domain of f3-tubulin, specifically amino acid
residues 217-233 (158,159). DTX was approved in 2002 for the treatment of advanced
breast cancer (160). In 2004, two randomized controlled trials found significant activity
of DTX in patients with HRPC since it increased their overall survival of patients (157).
The two clinical trials were designated TAX327 and SWOG 99-16. TAX327 was a three
arm study in which 1005 patients were randomized to receive either DTX for 3 week/3
times a week (75 mg/m ) plus low prednisone (10 mg daily), a DTX weekly (30 mg/m"
for 5 of 6 weeks) plus prednisone, or mitoxantrone (12 mg/m2 three weeks/three times a
week) plus prednisone (152). All three arms of the study lasted 30 weeks. The results
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obtained showed that patients in the 3 week/3 times a week DTX regimen had longer
survival (2.4 months more than mitoxantrone), reduction in pain, a greater that 50%
reduction in PSA, and improvement in the quality of life when compared to patients in
the mitoxantrone regimen (152). Patients in the DTX weekly regiment showed a trend
towards survival benefit but it was not statistically significant (152). Three years after this
study was performed, an update on the survival of patients showed that there was still a
significant improvement in survival associated with the 3 week/3 times a week DTX
regiment when compared to the mitoxantrone regimen (161).
The second clinical trial, SWOG 99-16, was designed to test if the combination of
two cytotoxic agents, DTX with estramustine, was better than just one cytotoxic agent
with a steroid. In this study the regimens were: DTX (60 mg/m2) in 3 week/3 times a
week plus estramustine (280 mg, three times daily) in 3 week/3 times a week; and
mitoxantrone (12 mg/m2) in 3 week/3 times a week plus prednisone (5 mg, twice daily)
(161). Results showed that the DTX regimen showed a 1.9 month overall survival,
improvement in time progression, and decrease in serum PSA concentration when
compared to the mitoxantrone regiment. However, the combination of DTX and
estramustine led to an increase in grade 3-5 gastrointestinal toxicities when compared to
the mitoxantrone regimen (161). The results clearly provided enough evidence to show
the effectiveness of a DTX regimen, leading to the Food and Drug Administration (FDA)
approval of DTX for treatment of HRPC in 2004 (162). Unfortunately, clinical treatment
with DTX often leads to undesirable side effects, including drug resistance (163-165).
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Taxane Resistance
Taxane resistance has been described as being multifactorial, multidrug in which
several mechanisms of resistance operate simultaneously (148). Some of these
mechanisms include impaired drug delivery and diverse cellular microenvironment.
Specifically, overexpression of the ABC family of drug transporters, variations in tubulin
isomers, and disruption of the apoptotic/survival pathways are known to lead to taxane
resistance (166-169). There are three principal ABC transporters involved in multidrug
resistance in humans; these are Pgp/MDR-1, MRP1 and ABCG2. Of these, the Pglycoprotein/multidrug resistance gene 1 (Pgp/MDR-1), also known as ABCB1, has been
implicated in DTX resistance (170). The ABC superfamily contains membrane proteins
involved in energy-dependent transport across the plasma membrane and are known to
extrude drugs out of cells, as well as other chemicals (170). Pgp, the gene product of
MDR1, is considered one of the most important ABC transporters since it confers
resistance to a wide variety of compounds due to its overexpression in cancer cells. It is
known that DTX is a substrate for Pgp and its overexpression compromises the efficacy
of the drug (171). Strategies to overcome Pgp/MDRl resistance are being developed and
include reversing MDR activity by distracting the drug-efflux pump, leading to decreased
extrusion and increased intra-cellular accumulation of the drug (172). A disadvantage
with this strategy is the increased toxicity as a result of higher doses of intracellular drug
in normal tissue. Another strategy is liposomal encapsulation of cytotoxic drugs, using
immunotherapy against Pgp, thus selectively killing cells that express Pgp (173-175).
Another mechanism of resistance associated with taxanes is the difference in
expression of p-tubulin isoforms (176). Microtubules composed of either pill- or pIV-

22

tubulin have been reported to be less sensitive to paclitaxel than microtubules assembled
from pil or unfractionated tubulin, suggesting that the cellular p-tubulin isotype
composition may play a role in paclitaxel sensitivity (177). Several other studies have
shown that resistance to paclitaxel correlates with an increased expression of class III and
IVa tubulin isotypes in the lung carcinoma cell lines A549-T12 and A549-T24 (178).
Similar findings were observed in the human prostate cancer cell line DU-145 (179).
Recent studies have shown that the same applies to DTX. For instance, Hayashi et al.
demonstrated that expression of class III p-tubulin significantly correlated with DTXresistance in patients with non-small cell lung cancer (NSCLC) (180). The same applies
to gastric and breast cancers (181,182).
The overexpression of survival proteins or downregulation of pro-apoptotitc
proteins has been associated with DTX-resistance in different types of cancer. Survival
proteins such as Bcl-2, Bcl-XL, members of the inhibitor of apoptosis protein (IAP)
family, and heat shock proteins (hsp), as well as the kinase Pim-1 and the tumor
suppressor p27, may result in aggressively growing tumors and contribute to resistance to
chemotherapeutic agents (183). Since most advanced tumors are insensitive to
chemotherapy, the resistance provided by these survival proteins becomes a major
problem at the clinical level. For this reason, new molecules that influence these survival
pathways, administered in combination with cytotoxic drugs have become the preferred
strategy in clinical studies to overcome intrinsic drug resistance (183). We will discuss
various survival proteins that are being studied mainly in PCa and that contribute to
taxane resistance, with special consideration to DTX.
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Bcl-2 is a proto-oncogene that prevents apoptosis induced by different stimuli
(184). It localizes on the mitochondrial outer membrane and prevents apoptosis by
suppressing the release of cytochrome c from the mitochondria (185). It is the primary
member of the Bcl-2 family of proteins which regulate the events determining whether or
not the pro-caspase/apoptosome complex assembles (186). All members of the Bcl-2
family contain one of four conserved Bcl-2 homology domains (BH1-BH4). Members of
this family are divided in 3 categories: anti-apoptotic, multidomain pro-apoptotic, and
BH3-only pro-apoptotic members (187). The importance of Bcl-2 in PCa is highlighted
by the observation that overexpression of this protein has been observed in PIN and PCa,
but not in BHP (188). In addition, increased expression of Bcl-2 induces resistance to
androgen ablation therapy, while its inhibition delays progression to androgenindependence and sensitizes PCa cells to therapy (189,190). Leonetti et al. showed that
PC3 cells treated with G3139 (antisense oligodeoxynucleotides for bcl-2) followed by
DTX treatment showed a higher apoptotic rate than treatment with DTX alone (191).
However, when the opposite sequence was done, DTX and then G3139, a reduced
apoptotic rate was observed, confirming the underscoring of first downregulating Bcl-2
and then treating with DTX (191). Furthermore, the DTX-resistant gastric cancer cell line
BGC-823 overexpressed bcl-2 when compared to its non-resistant counterpart (192).
Bcl-xL is a member of the Bcl-2 family with anti-apoptotic properties. Like Bcl-2,
Bcl-xL regulates the mitochondrial membrane potential and can block the release of
cytochrome c and AIF into the cytoplasm (193,194). Krajewski et al. observed that 100%
of prostate adenocarcinoma cases stained positively for Bcl-xL and the intensity
correlated with increasing Gleason score (195). A study combined antisense oligos
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against Bcl-xL and DTX (as well as other cytotoxic drugs) in the prostate cancer cell
lines PC3 and LnCaP (196). They showed that inhibition of Bcl-xL sensitized these cells
to DTX-induced death (196). Recently, Gleave’s group showed that inhibition of both
Bcl-2 and Bcl-xL with bispecific antisense oligos sensitized LnCaP cells to DTX-induced
cell death (197).
The inhibitor of apoptosis proteins (lAPs) comprise a family of proteins with one
or more baculovirus IAP repeat (BIR) domain repeats. To date, only eight members have
been identified: c-IAPl, C-IAP2, NAIP, Survivin, XIAP, Bruce, ILP-2, and Livin (186).
lAPs can block caspase 9 and caspase 3/7 activity leading to cell survival, and can be
negatively regulated by Smac, Omi, and XAF-1 (198). Krajewska et al. were the first to
show overexpression of several IAP members (cIAPl, cIAP2, XIAP, and survivin) in
PCa tissues (199). In addition, increased levels of these lAPs were observed during
disease progression in a transgenic mouse model of PCa (199). Survivin has been shown
to mediate resistance to paclitaxel therapy in PCa cells. Zhang et al. showed that
adenoviral inhibition of survivin lead to sensitization to cell death induced by paclitaxel
in PC3, DU 145 and LnCaP cells (200). Since paclitaxel and DTX are related taxanes, we
expect to observe similar effects of survivin inhibition in cells treated with DTX. In
addition, survivin was shown to be overexpressed in the DTX-resistant gastric cancer cell
line BGC-23 (192). Another IAP implicated in DTX-resistance is XIAP. Inhibition of
XIAP in epithelial ovarian cancer cells (EOC) sensitized cells to DTX-induced cell death
(201).

Heat shock proteins (Hsp) are molecular chaperones that are induced by heat and
other chemical and physical stresses (202). They are characterized as molecular
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chaperones which modify the structure and interactions of other proteins (203). The four
principal HSP families are HSP90, HSP70, HSP60 and small HSPs including Hsp27
(204). Hsp27 and Hsp70 are the most strongly induced during cellular stress (204).
Increased expression of Hsp27 has been observed in HRPC and its inhibition in PC3 cells
with antisense oligos lead to the sensitization in vitro and in vivo to paclitaxel-induced
cell death (205). The same group inhibited Hsp27 in PC3 cells with siRNA and observed
a decrease in viability (206). It should be noted that Hsp27 is a target gene of
LEDGF/p75 (Chapter 3 and (207)), and we cannot rule out the possibility that
upregulation of Hsp27, ERp57, and other stress proteins by LEDGF/p75 may contribute
to DTX resistance through the ability of these proteins to reduce ROS and prevent
lysosomal destabilization. Further studies combining inhibition of LEDGF/p75 and its
target genes with DTX treatment in moue models could lead to potential therapeutic
strategies against HRPC.
Clusterin is a cytoprotective chaperone protein expressed in virtually all tissues
and found in all human fluids (208-210). Clusterin is upregulated under conditions of
cellular stress (204). In the prostate, its expression levels have been correlated with
pathological grade on biopsy (210,211). The use of OGX-011 (a clusterin inhibitor) in
combination with DTX enhanced in vitro and in vivo the drugs antitumor activity (210).
The same group also reports (unpublished data reviewed in (204))that antisense oligos
against clusterin chemosensitizes PC3 to DTX-induced death.
Furthermore, Pim-1, a stress kinase implicated in PCa development and
progression, was highly expressed in a DTX-resistant HRPC cell line (CWR-R1/DTX)
and its inhibition led to sensitization to DTX-induced cell death (212). In DTX-resistant
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breast cancer cell lines it was observed, through a microarray analysis comparing
resistant and non-resistant cell lines, that reduced p27 expression was associated with
DTX resistance (213). p27 is a tumor suppressor involved in cell adhesion, apoptosis and
triggering of differentiation (214-217). The microarray analysis also showed
downregulation of pro-apoptotic genes TNFR1, Bax, and TRAILR2, with concomitant
upregulation of the survival factors HER2, IL-8, FGF2, Survivin and p38 MAPK (213).
Lastly, studies from our group described in this dissertation have provided evidence that
the stress protein lens epithelium derived growth factor/p75 (LEDGF/p75) might be
involved in the resistance of PCa cells against DTX treatment.

LEDGF/p75
LEDGF/p75, also known as dense fine speckled protein of 70 kDa (DFS70), and
its alternate spliced variant LEDGF/p52 were first described in 1998 by Ge and
colleagues as enhancers of transcriptional activation found in the nucleus of cells, with
LEDGF/p52 being the more potent co-activator (218). The LEDGF gene was mapped to
chromosome 9p22.2, a region implicated in cancer (219). The LEDGF gene encodes 15
exons and 14 introns, were LEDGF/p75 is encoded by exons 1-15 and LEDGF/p52 by
exons 1-9 and part of intron 9 (218). Additional novel spliced variants of LEDGF were
detected by Huang et al. (220). Both proteins belong to the hepatoma derived growth
factor (HDGF) family, sharing homology in the N-terminal region where a PWWP
domain (residues aa 1-98) is found (221-223). In addition, both proteins share a nuclear
localization signal (NLS) at residues aa 148-156, a Tat like sequence within the NLS

27

1

PWWP
domain

98

AT
NLS hooks

325

530

p75
CTT

|$ p52

#/// /
O

O

<T <T

O

£

$/// ^
4)

<Vv4r<l4r

LEDGF/p75
m

p52
p-Actin

28

Figure 4. Schematic representation of the domain structure of LEDGF/p75 and
LEDGF/p52 and expression of both proteins in cancer cell lines. A. The shared regions of
both proteins contain the PWWP domain, the nuclear localization signal (NLS), the basic
leucine zipper (bLZ) domain overlapping the helix-tum-helix (HTH) region, and an AThook motif. The LEDGF/p52 C-terminal end contains eight amino acids non-identical to
LEDGF/p75. The LEDGF/p75 C-terminal contains an integrase binding domain (IBD).B.
Immunoblotting analysis of endogenous protein expression of LEDGF/p75 and p52 in a
panel of human normal and cancer cell lines. Figure generated by Melanie MediavillaVarela which was included in Brown-Bryan et al. (224).

29

region, a basic leucine zipper (bLZ) sequence that overlaps with a helix-tum-helix (HTH)
region in residues aa 154-175, and two AT-hooks in residues aa 178-183 and 191-197
(Figure 4) (225,226). The C-terminus of LEDGF/p75, absent in LEDGF/p52, contains a
region that shares sequence homology with HDGF-related protein 2 (HRP-2) and has
been defined as the HIV-1 integrase binding domain (IBD) (227,228). In addition, this
domain overlaps with the epitope recognized by human anti-LEDGF/p75 autoantibodies
(229). As can be observed in Figure 4, LEDGF/p75 and p52 are expressed at low levels
in normal cells. However, their expression increases in cancer cells, with the levels of
LEDGF/p75 much higher than those of p52.

LEDGF/p75 and Inflammatory Disorders
Autoantibodies to LEDGF/p75 have been found in sera from patients with several
inflammatory conditions (230). Production of autoantibodies against nuclear proteins has
been a immunological feature of systemic autoimmune diseases which might be used for
their differential diagnosis (231). For this reason the prevalence of autoantibodies against
LEDGF/p75 was studied, in anticipation that it could be used for diagnosis.
Autoantibodies against LEDGF/p75 were found in patients with various inflammatory
conditions such as atopic dermatitis (AD) (28% by Ochs et al. and 71.4% by Ayaki et
ah), Vogt-Koyanagi-Harada (VKH) disease (66.7%), asthma (16%), interstitial cystitis
(8.7%), and Sjrogen’s syndrome (6.9%), psoriasis (4.5%), chronic fatigue syndrome
(3.3%), and scleroderma (2.5%) (232-235).
However, in a recent study, autoantibodies against LEDGF/p75 were found in 64
out of 597 healthy patients, which represented 54% of the total antinuclear autoantibody
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(ANA) positive population (234). In addition, Dellavance et al. found anti-LEDGD/p75
antibodies frequently in the context of a general laboratory ANA routine, in patients with
diverse systemic and organ-specific autoimmune diseases, as well as asymptomatic
patients (236). This discrepancy in the disease association of these antibodies could be
due to the fact that the sera from the previous studies was from a collection of
laboratories dedicated to autoimmune, allergic, and ophthalmologic disease, while the
sera for this study was collected from a general laboratory ANA routine. These studies
suggest that even though there is a prevalence of LEDGF/p75 autoantibodies in several
inflammatory conditions, a thorough assessment of the disease-relevance of this
autoantibody remains to be done.

LEDGF/p75 and the Cellular Stress Response
LEDGF/p75 was originally thought to be a lens epithelial cell (EEC) growth
factor since its overexpression enhanced the survival and growth rate of mouse LECs,
cos7 cells, human fibroblasts, and keratinocytes (207,237). In addition, deprivation of
LECs of LEDGF/p75 with anti-LEDGF/p75 antibodies reduced its nuclear localization
and induced cell death (238). Further analysis of LEDGF/p75 revealed that its function
wasn’t that of a growth factor but of a survival protein that protected mammalian cells
from thermal, oxidative and serum stress through the transcriptional activation of stress
proteins such as heat shock protein 27 (Hsp27) and ab-crystallin (207,237,239-241). This
upregulation is presumed to occur through the binding of LEDGF/p75 to heat shock
elements (HSE; nGAAn) and stress related elements (STRE; A/TGGGGA/T) in the
promoter regions of the stress-related proteins Hsp27, ab-crystallin, antioxidant protein 2
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or peroxiredoxin 6 (AOP2/Prdx6), and alcohol dehydrogenase (ADH) (160,242-244).
This was confirmed in LEDGF/p75 overexpressing cells which showed a five fold
increase in the mRNA levels of stress-related proteins when compared to the empty
vector expressing cells (241).
The pro-survival function of LEDGF/p75 appears to be attenuated by TGF-pl, a
known regulator of apoptosis which down-regulates LEDGF/p75 gene transcription and
protein expression in human EEC (245). This attenuation was proposed to occur through
two possible mechanisms. First, the promoter region of LEDGF/p75 includes a regulatory
element called TIE (TGF-pl inhibitory element) that is required for TGF-pl inhibitory
effects (246). This element was mutated in the promoter region of LEDGF/p75 and
showed that the repressive effect of TGF-pi on LEDGF/p75 gene transcription was
abolished (245). Second, treatment with TGF-pi induces apoptosis through the activation
of caspases, which was shown in our laboratory to cleave LEDGF/p75 into well defined
fragments, abolishing its survival function (222). Recently, Fatma et al. confirmed the
role of TGF-pl as a repressor of LEDGF/p75 in a mouse cell line derived from a Prdx6
knockout model (Prdx6' ') (247). This cell line displayed reduced LEDGF/p75 levels, but
had increased mRNA and protein levels of TGF-pl, thus confirming its role in
LEDGF/p75 repression (247).
Another protein showing a similar repression mechanism of LEDGF/p75 on
survival activity is the anti-apoptotic protein Bcl-2 (248). Bcl-2 has been shown to
prevent cell death induced by serum and growth factor depletion, as well as gamma
irradiation (249-251). It also protects mammalian cells from oxidative stress (252,253).
However in some cell lines Bcl-2 upregulation doesn’t protect from oxidative stress and
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oxidative stress-induced apoptosis (254,255). Therefore, depending on the cell line, Bcl-2
might or might not show a protective effect to stress or oxidant-induced cell death. Mao
et al showed that in rabbit LECs (rLECs) Bcl-2 stable clones could not metabolize
hydrogen peroxide (H2O2), hence they showed a higher apoptotic index in the presence of
H2O2 than in stable clones expressing the empty vector (248). The attenuation in H2O2
metabolism was due to Bcl-2’s ability to down-regulate ab-crystallin by influencing the
promoter binding activity of LEDGF/p75 (248).

LEDGF/p75 and HIV integration
During the past six years LEDGF/p75 has been tightly associated with HIV
integration. Debyser’s group was the first to report that HIV-1 integrase (IN) forms a
nuclear complex with LEDGF/p75, which is crucial for directing integration of HIV-1 by
tethering the HIV-IN to host chromosomes (256,257). This interaction occurred via the
IBD in the C-terminal region of LEDGF/p75 (residues 347-429) (227,228). In addition,
this interaction is direct and confined only to lentiviruses (258-260). Earlier studies
concluded that HIV-IN had a NLS signal, but recent findings showed that the lend viral
IN proteins are cytoplasmic in the absence of LEDGF/p75, leading to the tethering model
in which LEDGF/p75 links HIV-IN to chromatin (261). Furthermore, LEDGF/p75
interaction with HIV-IN leads to an increase in integrase stability (262,263). HIV-IN is
ubiquitylated and subjected to degradation, but in the presence of LEDGF/p75 is
protected from degradation (260).
Two lines of evidence show that LEDGF/p75 participates in HIV-1 replication.
First, a single mutation disrupting the LEDGF/p75-IN interaction was demonstrated to

33

disrupt HIV-1 replication (262). Second, transient and stable knockdown of LEDGF/p75
caused a reduction in HIV-1 integration and replication (264,265). However, LEDGF/p75
knockdown does not completely abolish HIV integration suggesting that other factors
might be involved in this process (260,263). Recently, various investigators reported that
the LEDGF/p75 IBD interacts with the myc-associated protein JP02 and the transposasederived DDE domain of PogZ (266,267). Further studies are needed to determine if these
interacting partners might act as restriction factors to viral replication.

LEDGF/p75 and Chromosomal Translocations
LEDGF/p75 has also been associated with chromosomal translocations in the
t(9;l I)(p22;pl5) in both adult and pediatric acute myeloid leukemia (AML) and chronic
myeloid leukemia (CML) (268-270). This chromosomal translocation results in the
fusion of the N-terminus of the nucleoprotein 98 (NUP98) with the C-terminus of
LEDGF/p75. The NUP98 gene is involved in 1 Ip 15 translocations in both de novo and
therapy related AML as well as T-cell acute lymphoblastic leukemia (271). Furthermore,
it is a component of the nuclear pore complex and is involved in nucleocytoplasmic
transport as a docking protein (272). The N-terminus of NUP98 contains 28 FXFG
repeats, which are known to interact with CBP/p300 and act as transactivation domains.
Although the role of the NUP98-LEDGF/p75 fusion in AML patients is still unknown, it
is possible that this fusion might lead to enhanced transcriptional activity of LEDGF/p75,
which would be supported by the observation that the N-terminus of LEDGF/p75 may
have transcription regulatory functions (273). Recently, LEDGF/p75 was established as a
crucial factor required for both the oncogenic and tumor suppressor functions of the
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mixed-lineage leukemia (MLL)/menin complex (274). Menin is an essential cofactor for
MLL oncoproteins to maintain leukemic transformation (274). Although in endocrine
linage cells menin acts as a tumor suppressor in multiple endocrine neoplasia type 1
(MEN 1) tumorigenesis, in hematopoetic cells menin serves as a cofactor for MLL
oncoproteins (275). They sustain HOX gene misexpression and maintain leukemic
transformation (276-278).

LEDGF/p75 and Apoptosis
Our group reported previously that during apoptotic cell death LEDGF/p75 was
cleaved into fragments of about 72, 68, 65 and 58 kDa by caspases-3 and -7. The
predominant fragment was 65 kDa, which is truncated in the N and C termini (222).
FlepG2 cells stably overexpressing LEDGF/p75 were resistant to serum deprivationinduced cell death, while overexpression of the cleavage fragments did not protect the
cells (222). In addition, overexpression of the 65 kDa fragment appeared to enhance cell
death, which led us to propose that it might be acting as a dominant negative protein
inhibiting cell proliferation or inducing cell death under stress conditions (222). Together,
these results suggest that proteolytic cleavage of LEDGF/p75 during apoptosis abolishes
its survival activity.
Furthermore, our group also demonstrated that the LEDGF/p75 alternative splice
variant LEDGF/p52 is also cleaved by caspases-3 and -7, generating fragments of 48 and
38 kDa (224). Transient overexpression of LEDGF/p52 as well as the p38 fragment
displayed classical features of apoptosis in various tumor cell lines (224). The p38
fragment was found to inhibit the transcriptional function of LEDGF/p75, which is
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necessary for its stress survival activity. These results suggest that while LEDGF/p75 acts
as a stress survival protein, its spliced variant p52 has the opposite effect, an inducer of
apoptosis that antagonizes the pro-survival function of LEDGF/p75. Consistent with
these findings, we demonstrated that human cancer cell lines express high levels of
LEDGF/p75 but low levels of p52 (224). Further studies on the expression and function
of these variants in human cancers could lead to the development of potential therapeutic
strategies to modulate the stress survival function of LEDGF/p75 in tumos.

LEDGF/p75 in PCa
Our group demonstrated that autoantibodies to LEDGF/p75 are present in sera
from PCa patients (279). Furthermore, we detected by immunoblotting analysis an
upregulation of LEDGF/p75 expression in PCa cell lines but not in normal prostate cells
(279). Immunohistochemical analysis showed that 93% of prostate tumors expressed high
levels of LEDGF/p75 when compared to normal prostate tissue (279). These were the
first studies linking high LEDGF/p75 expression with cancer. In addition, we were able
to show attenuation of DTX-induced cell death in RWPE-2 cells stably overexpressing
LEDGF/p75 (Figure 5). We presumed that this protective event only occurs when cells
undergo oxidative stress-induced cell death via a caspase-independent pathway since no
protection was observed in the same cells overexpressing LEDGF/p75 when treated with
known caspase-dependent apoptosis-inducers (TRAIL and staurosporin) (data shown in
Chapters 2 and 3). This finding was consistent with the observation of

36

DTX 3jj,M (24h)
100

p<0.001

90
80
&

70

I

60

|

50

S

40

l

30
20
10
0

III

RWPE-2

Vec 2

Vec 3

37

Figure 5. Overexpression of LEDGF/p75 attenuates DTX-induced cell death. Viability
assay, performed using crystal violet staining, shows attenuation of DTX-induced cell
death in RWPE-2 clones overexpressing LEDGF/p75 (LEDGF 8 and 12) when compared
to RWPE-2 cells transfected with empty vector (vec 2 and 3) or parental RPWE-2 cells.
Errors bars represent the standard deviation of at least three independent experiments
done in triplicate. The data presented in this figure was generated by Dr. Tracy R.
Daniels, a former member of our laboratory.
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Daugaard et al. that LEDGF/p75 may control caspase-independent lysosomal cell death
in HeLa and MCF7 cells (280). Knockdown of LEDGF/p75 with siRNA oligos induced
an apoptosis-like cell death and distinct of classic cytochrome-c and caspase mediated
apoptosis in HeLa cells associated with activation of the lysosomal cell death pathway. In
addition, overexpression of LEDGF/p75 enhanced the lysosomal stability and resistance
to lysosome-targeting drugs in HeLa and MCF-7 cells as well as the tumorigenic
potential of mice bearing HeLa-LEDGF/p75 tumors (280). These findings led us to
explore whether DTX induces cell death via a caspase-independent lysosomal pathway,
challenging the paradigm that apoptosis is the main mechanism by which the drug
induces cytotoxicity.

DTX-induced Cell Death
DTX and Apoptotic Cell Death
Apoptosis has been proposed as the main mechanism of cell death induced by
taxanes (281-283). Since DTX is a second generation taxane, it has been assumed that the
mode of cell death induced by this drug would be the same or similar to that of its
parental drug paclitaxel. However, since its conception, some differences were observed
between the two drugs. In several murine and human cell lines, the cytotoxic levels of
DTX have been higher than those observed by paclitaxel (284,285). In addition, DTX
exhibits linear pharmacokinetics and is retained intracellularly longer when compared to
paclitaxel (286,287). For these reasons a better understanding of the mechanisms of
action of DTX is needed. Understanding these mechanisms also have implications for
gaining insights into how PCa cells develop resistance to this drug.
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It is well established that DTX promotes apoptosis in cancer cells. HL-60 and
K562 cells exhibited mainly caspase-3 activation after DTX treatment, while caspase-2
activation was observed in various melanoma cell lines (288,289). In HT137 cells, DTX
caused DNA fragmentation, impaired the mitochondrial membrane potential, confirming
the activation of the apoptotic pathway by (290). In DU 145 cells treated with low DTX
concentrations (5 nM), apoptosis was associated with the activation of caspase-3, PART
cleavage, and downregulation of XIAP (291).

DTX and Non-apoptotic Cell Death
Despite the clear connection to the apoptotic pathway, other modes of DTXinduced cell death have been observed, including mitotic catastrophe, treatment-induced
senescence, and lytic necrosis (292). Schimming et al. observed that in several types of
cancer (adenocarcinomas, squamous cell carcinomas, sarcomas and lymphomas) that
were inoculated subcutaneously in C3Hf/Kam mice, mitotic arrest was the main effect of
DTX treatment, with an apoptotic index of less than 4% (293). Histological analyses of
DTX-responsive tumors revealed massive destruction by cell lysis, not by apoptosis,
which was prominent between 12 and 24 hours after treatment (293). A study by
Hernandez-Vargas et al. in breast cancer cells, showed mitotic arrest followed by
apoptosis at high concentrations of DTX (294). However, aberrant mitosis followed by
necrosis was observed when low concentrations of DTX were used (294). Morse et al.
concluded that mitotic catastrophe was the major response to DTX treatment in three
human breast cancer cell lines, with additional death attributed to other non-apoptotic
mechanisms (292). These studies underscore the importance of evaluating the multiple
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mechanisms of cell death induced by DTX, and their role in the development of DTX
resistance.

Purpose and Significance of this Dissertation
The purpose of this dissertation was to study the role of LEDGF/p75 as a
protector against a selective type of cell death induced mainly by chemotherapeutic
agents or oxidative stress in PCa cells. The attenuation of DTX-induced cell death, and
not TRAIL/ActD or STS induced cell death, observed in RWPE-2 cells stably
overexpressing LEDGF/p75, led to the hypothesis that LEDGF/p75 confers selective
resistance to oxidative stress-induced cell death possibly through the upregulation of
stress related proteins. To gain insight into the mechanism by which LEDGF/p75
confers this resistance we pursued the following aims:
1. To characterize the mechanism by which docetaxel induces cell death and possible
attenuation of cell death by LEDGF/p75.
2. To investigate the regulation of ERp57 by LEDGF/p75 in prostate cancer cells.
3. To determine whether functional inactivation of LEDGF/p75 and ERp57 sensitizes
prostate cancer cells to oxidant-induced death.
Our studies showed that LEDGF/p75 conferred resistance to DTX and tert-butyl
hydrogen peroxide (TBHP) induced cell death through the reduction of ROS and
lysosomal destabilization in PCa cells. In addition, we showed that the mechanism by
which LEDGF/p75 conferred this resistance may involve the upregulation of the thioloxidoreductase ERp57.
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The proposed studies will provide insights into the mechanism underlying
resistance to oxidative stress-induced cell death in PCa. In addition, these studies are
highly significant because they will contribute to the development of innovative
molecular targeting strategies that would act synergistically with traditional
chemotherapeutic agents in PCa.
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CHAPTER TWO
DOCETAXEL-INDUCED PROSTATE CANCER CELL DEATH INVOLVES
CONCOMITANT ACTIVATION OF CASPASE AND LYSOSOMAL PATHWAYS
AND IS ATTENUATED BY LEDGF/P75
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Abstract
Background: Hormone-refractory prostate cancer (HRPC) is characterized by poor
response to chemotherapy and high mortality, particularly among African American men
when compared to other racial/ethnic groups. It is generally accepted that docetaxel, the
standard of care for chemotherapy of HRPC, primarily exerts tumor cell death by
inducing mitotic catastrophe and caspase-dependent apoptosis following inhibition of
microtubule depolymerization. However, there is a gap in our knowledge of mechanistic
events underlying docetaxel-induced caspaseindependent cell death, and the genes that
antagonize this process. This knowledge is important for circumventing HRPC
chemoresistance and reducing disparities in prostate cancer mortality.
Results: We investigated mechanistic events associated with docetaxel-induced death in
HRPC cell lines using various approaches that distinguish caspase-dependent from
caspase-independent cell death. Docetaxel induced both mitotic catastrophe and caspasedependent apoptosis at various concentrations. However, caspase activity was not
essential for docetaxel-induced cytotoxicity since cell death associated with lysosomal
membrane permeabilization still occurred in the presence of caspase inhibitors. Partial
inhibition of docetaxel-induced cytotoxicity was observed after inhibition of cathepsin B,
but not inhibition of cathepsins D and L, suggesting that docetaxel induces caspase
independent, lysosomal cell death. Simultaneous inhibition of caspases and cathepsin B
dramatically reduced docetaxel-induced cell death. Ectopic expression of lens epitheliumderived growth factor p75 (LEDGF/p75), a stress survival autoantigen and transcription
co-activator, attenuated docetaxel-induced lysosomal destabilization and cell death.
Interestingly, LEDGF/p75 overexpression did not protect cells against DTX-induced
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mitotic catastrophe, and against apoptosis induced by tumor necrosis factor related
apoptosis inducing ligand (TRAIL), suggesting selectivity in its pro-survival activity.
Conclusions: These results underscore the ability of docetaxel to induce concomitantly
caspase dependent and independent death pathways in prostate cancer cells. The results
also point to LEDGF/p75 as a potential contributor to cellular resistance to docetaxelinduced lysosomal destabilization and cell death, and an attractive candidate for
molecular targeting in HRPC.
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Introduction
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and the
second leading cause of male cancer deaths in the U.S. [1]. PCa also presents the greatest
racial disparity of any cancer in the U.S., with higher incidence and mortality in AfricanAmerican men (AA), compared to other ethnic groups [2,3], A factor contributing to
these disparities is the more aggressive and perhaps more therapy-resistant form of the
disease observed among AA men [2,3]- Understanding the underlying causes of this
increased tumor aggressiveness would require a multi-prong approach that includes
evaluation of potential racial/ethnic differences in prostate tumor biology, identification
of gene-environment interactions leading to prostate inflammation, elucidation of
molecular mechanisms associated with PCa chemoresistance, and development of more
effective therapeutic interventions for HRPC. Docetaxel (DTX, Taxotere®), a semi
synthetic analog of paclitaxel, has emerged in recent years as the standard of care for
chemotherapy of HRPC [4], Unfortunately, most HRPC patients treated with DTX
ultimately manifest resistance to the drug and succumb to the disease. The mechanisms
underlying resistance to DTX in HRPC appear to be diverse and poorly understood;
however, a growing body of evidence implicates cellular anti-apoptotic, stress, and redox
signaling pathways in the development of HRPC and DTX resistance [5-10]. Attaining a
mechanistic understanding of DTX-induced cell death and DTX resistance in PCa would
facilitate the identification of new molecular targets and the development of rational
therapeutic strategies aimed at sensitizing HRPC to this and other anti-tumor drugs. It is
generally accepted that DTX primarily exerts tumor cell death by inducing mitotic
catastrophe and caspase-2 and -3-dependent apoptosis following inhibition of
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microtubule depolymerization [11-16]. DTX has also been reported to induce non
apoptotic death in tumor cells, both in vitro and in vivo, depending on the dose, cell type,
and tumor microenvironment [11,15,17]. While mechanistic insights into non-apoptotic,
caspase-independent cell death induced by paclitaxel have been reported [18,19],
knowledge of mechanistic events underlying DTX-induced caspase-independent cell
death is very scarce. Caspase-dependent and independent cell death pathways co-exist in
tumor cells and can be triggered in parallel by therapeutic agents [20-22]. While most
efforts in targeting cellular survival pathways have focused on inactivating proteins that
antagonize caspase-dependent pathways, there is growing consensus that targeting
survival proteins that antagonize caspase-independent or non-apoptotic cell death might
be a promising strategy for increasing the effectiveness of chemotherapeutic drugs [2022].
The lens epithelium derived growth factor p75 (LEDGF/p75) is emerging as a
stress response protein that promotes cell survival against death induced by stressors such
as oxidative stress, heat shock, serum starvation, and chemotherapy [23-28]. This protein
is also known as transcription co-activator p75 (TCP75), PC4 and SFRS1 interacting
protein (PSIP), and dense fine speckled autoantigen of 70 kD (DFS70) [29-31].
LEDGF/p75 has been identified as a member of the hepatoma-derived growth factor
family [32], a NUP98-fusion protein resulting from chromosomal translocations in
leukemias [33], an autoantigen in diverse autoimmune and inflammatory conditions
[30,34-36], and a key cellular co-factor for the chromosomal integration of HIV-1 [3739]. LEDGF/p75 is presumed to promote malignant transformation and resistance to
stress-induced cell death via either direct binding to promoter regions of stress survival
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and anti-oxidant genes, or protein-protein interactions leading to transcriptional activation
of cancer related genes [40-42]. The stress-survival activity of LEDGF/p75 appears to be
regulated by alternative splicing resulting in the removal of its carboxyl C-terminal
domain, and by caspase mediated disruption of both its amino (N) and C-terminal
domains [25,43]. We reported previously that LEDGF/p75 is the target of autoantibody
responses in some patients with PCa, and that its expression is upregulated in advanced
stage PCa [44]. LEDGF/p75 expression was also found elevated in human breast and
bladder carcinomas, and its ectopic overexpression increased the tumorigenic potential of
human cancer cells in murine models [27], In this study we provide evidence that
treatment of HRPC cells with DTX, in addition to inducing mitotic catastrophe and
caspase-dependent apoptosis, induces a caspase independent cell death pathway that
involves lysosomal destabilization and cathepsin B activation. We also show that ectopic
overexpression of LEDGF/p75 attenuates DTX-induced lysosomal destabilization and
cell death, but not DTX-induced mitotic catastrophe or apoptosis induced by tumor
necrosis factor related apoptosis inducing ligand (TRAIL). These results underscore the
ability of DTX to activate multiple cell death pathways, and point to LEDGF/p75 as a
potential contributor to DTX resistance in PCa.

Materials and Methods
Cell Lines, Antibodies and Reagents
PCS, DU145 and RWPE-2 cell lines were obtained from American Type Culture
Collection (ATCC) and cultured according to ATCC recommendations. The following
antibodies were used: mouse monoclonal anti-poly (ADP-ribose) polymerase (PARP)
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AB-2 (Calbiochem), mouse monoclonal anti-(3-actin (Sigma-Aldrich), goat polyclonal
anti-cathepsin B (Santa Cruz Biotechnology), and horseradish peroxidase (HRP)-labeled
secondary IgG antibodies (Zymed). Human autoantibodies to LEDGF/p75 were a kind
gift from Dr. Edward Chan (University of Florida, Gainesville). The broad caspase
inhibitor benzylocarbonyl Val- Ala-Asp-fluoromethyl ketone (Z-VAD-FMK) and the
specific caspase-2 inhibitor N-acetyl-Val Asp-Val-Ala-Asp-aldehyde (Ac-VDVADCHO) were purchased from Biomol International. DTX was purchased from LC
Laboratories. Recombinant human TRAIL and actinomycin D were purchased from
R&D Systems. Staurosporine (STS), N-acetyl-Asp-Glu-Val-Asp-7-amino- 4methylcoumarin (Ac-DEVD-AMC, fluorogenic caspase-3/7 substrate), and Ac-VDVADAMC (fluorogenic caspase-2 substrate) were purchased from Axxora. Inhibitors of
cathepsin B (CA-074Me), cathepsin L (cathepsin L inhibitor I) and cathepsin D
(pepstatin A) were obtained from EMD Biosciences. The cathepsin B fluorogenic
substrate Magic Red MR-(RR)2, Acridine Orange (AO), and Hoescht 33342 were
purchased from Immunochemistry.

Induction of Cell Death
Cell death was induced by treatment with DTX (various concentrations),
TRAIL/actinomycin D (100 ng/ml each), or 4 pM STS for up to 48 h. In some
experiments cells were preincubated with either 100 pM of Z-VAD-FMK, 100 pM of
Ac-VDVAD-CHO, 100 pM cathepsin B inhibitor, 150 pM cathepsin L inhibitor, or 100
pM cathepsin D inhibitor for 1 h prior to exposure to the cytotoxic drugs. Cells were
visualized on an Olympus 1X70 microscope equipped with Hoffmann Modulation
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Contrast (Olympus American). Images were acquired using a digital Spot Imaging
System (Diagnostic Instruments).

Cell Viability Assays
Cells seeded in 96-well plates (104 cells per well) were treated with cytotoxic
drugs or inhibitors, washed with phosphate buffered saline (PBS), and fixed in 4%
paraformaldehyde for 1 h at 4°C. Cells were then washed three times with distilled water,
and Accustain Crystal Violet solution (Sigma-Aldrich) (1:4) was added to each well
followed by incubation for 20 minutes at room temperature. Plates were washed with
distilled water to remove excess dye and then dried at room temperature. Acetic acid
(10% v/v) was added to each well for 10 minutes and absorbance was measured at 570
nanometers (nm) using a pQuant microplate reader (Bio-tek Instruments). Cell viability
was also determined using a modified (3-(4,5-dimethylthiazol-2-yl)- 2,5diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich, St. Louis, MO). Briefly, cells
were seeded in 96-well plates (104 cells per well) and then treated with cytotoxic drugs or
inhibitors. MTT was then added to each well (final concentration, 1 mg/ml) and plates
were incubated in a 5% C02 incubator at 37°C for 1 h. Plates were centrifuged at 2,000
rpm for 30 minutes to avoid loss of floating cells. Supernatants were discarded and 150 pi
of dimethylsulfoxide (DMSO), were added to each well. Absorbance was measured at
450 nm.
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Caspase Activity Assays
Caspase activity assays were performed as described previously [43]. Briefly,
cells were seeded in black, clear-bottomed 96-well plates (104 cells per well). At the
conclusion of treatment with cytotoxic drugs or inhibitors, cells were incubated with 50
pi of 3X caspase buffer [150 mM Hepes pH 7.4, 450 mM sodium chloride, 150 mM
potassium chloride, 30 mM magnesium chloride, 1.2 mM ethylene glycol-bis(2aminoethylether)-A,A,A',A'-tetraacetic acid (EGTA), 30% sucrose, 10% CHAPS, and
1.5% NP-40], 30 mM dithiothreitol (DTT), 3 mM phenylmethanesulphonylfluoride
(PMSF), and 75 pM of the fluorogenic peptide substrates Ac-DEVD-AMC (caspase-3/7)
or Ac-VDYAD-AMC (caspase-2) for 2 h at 37°C, followed by incubation at room
temperature for 12 h. Absorbance was then read in a FLX800 Microplate Fluorescent
Reader (Bio-tek Instruments) at excitation of 360 nm and emission of 460 nm. Fold
activity was determined by normalizing to one the absorbance values for untreated cells.

Immunoblotting
Equal amounts of protein from whole cell lysates were separated by sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), blotted onto polyvinyl
difluoride (PVDF) membranes, and analyzed by immunoblotting as described previously
[25].

Analysis of Mitochondrial Membrane Potential (MMP)
Cells (3 xlO5 per well) were grown in 6-well plates. After treatment with DTX,
7.pi of S^’^h’-tetrachloro-Cl’^^’-tetraethyl-benzimidazoly-carbocyanine iodide (JC-

52

1, stock: 5 mg/ml) were added per ml to each well, followed by incubation at 37°C for 30
minutes. Floating cells were collected and combined with cells harvested by
trypsinization. JC-1 retained in 20,000 cells was measured at 530 nm (FL-1, green) and
590 nm (FL-2, red) using a FACScalibur flow cytometer (BD Biosciences). CellQuest
Pro software was used for data analysis.

Flow Cytometric Cell Cycle Analysis
Cells (3 x 105 per well) were grown in 6-well plates. After treatment with DTX,
floating cells were collected and later combined with attached cells harvested by
trypsinization. Cells were resuspended in PBS, fixed with 2 ml of ice-cold 70% ethanol,
and incubated for 30 minutes at 4°C. Cell pellets were collected by centrifugation (5,000
rpm for 5 minutes) and resuspended in 400 pi of PBS, 50 pi of propidium iodide (PI)
solution (0.6 mM) and 50 pi of RNase A (1 mg/ml). After incubation for 30 minutes in
the dark at 37°C, cells were analyzed for DNA content using a FACScalibur flow
cytometer. Fluorescence from the PI-DNA complex was estimated on a minimum of
50,000 cells per sample and analyzed with CellQuest Pro software.

Analysis of Lysosomal Membrane Permeabilization
The Acridine Orange (AO) method was used to analyze lysosomal membrane
permeabilization (LMP) as described previously [45]. Briefly, cells growing in 6-well
culture plates were exposed to AO (5 pg/ml) and counterstained with Hoescht 33342 (1
pg/ml) for 20 minutes at 37°C. Cells were then examined under an Olympus BX50
epifluorescence microscope using a UMPlanPI 60X/0.90W water immersion objective
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(Olympus). Images were acquired using a digital Spot camera system (Diagnostic
Instruments).

Cathepsin B Activity Assay
Cathepsin B activity was detected using the fluorogenic susbtrate Magic Red MR(RR)2 (Immunochemistry Tech). Briefly, cells growing in 6-well culture plates were
exposed for 1 hour to the cathepsin B substrate, rinsed twice with PBS, and
counterstained with Ipg/ml of Hoechst 33342 for nuclear visualization. Cells were
directly examined under an Olympus BX50 epifluorescence microscope using a
UMPlanPI 60X/0.90W water immersion objective. Images were acquired using a digital
Spot camera system.

Generation of Cell Lines Stably Overexpressing LEDGF/p75
The LEDGF/p75 cDNA was previously cloned into the mammalian expression
vector pcDNA3.1+ (Invitrogen) [25]. Both the pcDNA3.1+ empty vector and
pcDNA3.1+/LEDGF/p75 vector were transfected into PC3 cells using the Fugene 6
method (Roche). Forty-eight hours post-transfection, cells were trypsinized and seeded
into 6-well plates. Selection of stable transfectants was achieved by adding G418 (Fisher
Scientific) to the cell cultures. Colonies were expanded and assayed for increased
expression of LEDGF/p75 by immunoblotting. Clones overexpressing LEDGF/p75 were
selected for further expansion and stored in liquid nitrogen.
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Real-Time PCR
Total RNA was extracted from PCS cells with TRIzol Reagent (Invitrogen), and
single stranded cDNA was constructed using Superscript III polymerase (Invitrogen) and
oligo-dT primers. Real-time polymerase chain reaction (RT-PCR) was performed using
the iCycler (Bio-Rad) and SYBR Green PCR master-mix reagents (Abgene). The
following primers were used: LEDGF/p75 forward 5’-TCAAGTCAACAGGCAGCAAC
-S’; LEDGF/p75 reverse 5’- TAGCTGCAGGTCGTCCTCTT-3’; Cofilin (CEL) forward
5’ AAGTCTTCAACGCCAGAGA-3’; CEL reverse 5’GGCCCAGAAGATAAACACCA-3’. Primers were used at a concentration of 4pM.

Results
DTX-induced Cell Death Involves Caspase-Activation but is not
Entirely Caspase-Dependent
To determine whether DTX-induced cytotoxicity in PCa cells is dependent on the
activation of caspases, particularly caspase-2, we first examined the activity of caspases-2
and -3 in the hormone-refractory PCa cell lines PC3, DU 145, and RWPE-2 after
treatment with increasing DTX doses, ranging from 0.01 pM to 5 pM. Since the observed
results for these and some subsequent experiments were relatively similar with all the
doses and cell lines, and for the sake of brevity, we opted to show only data for PC3 cells
treated with relatively low (0.1 pM) and high (3 pM) concentrations. These correspond to
plasma DTX concentrations achieved in treated PCa patients during the initial hours post
infusion [12,46].
Both concentrations of DTX induced gradual activation of caspases-2 and 3
during treatment of PC3 cells for up to 48h (Fig. 6A). Caspase-2 activity was abolished
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by pretreatment of cells with the specific inhibitor Ac-VDVAD-CHO, whereas both
caspases were completely inhibited with the broad-caspase inhibitor Z-VAD-FMK (Fig.
6A). In light of this, most subsequent experiments were conducted only in the presence of
Z-VAD-FMK. We observed that the caspase substrates PARP and LEDGF/p75 [25] were
cleaved into their signature apoptotic fragments of p85 and p65, respectively, during
DTX-induced PCS cell death (Fig. 6B). However, no cleavage was observed in the
presence of Z-VAD-FMK, consistent with inhibition of caspase activity.
To further highlight the importance of the caspase-dependent pathway in DTXinduced PCS cell death we analyzed the effect of DTX on mitochondrial membrane
potential (MMP). Loss of MMP was induced at both concentrations of DTX after 48 h of
exposure to the drug, and was inhibited by Z-VAD-FMK, confirming its dependence on
caspase activation (Fig. 6C). We also measured DNA fragmentation by flow cytometric
analysis of DNA content. As observed in Fig. 6D, treatment with either 0.1 or 3.0 pM
DTX for 48 h led to significant increase in the subGl cell population. In the presence of
Z-VAD-FMK there was a decrease in the subGl cell population concomitant with
increase in the G2/M fraction. Taken together, the data presented in Fig. 5 indicate that
both low and high doses of DTX induce caspase activation, caspase substrate cleavage,
loss of MMP, and DNA fragmentation.
To explore the possibility that DTX-induced cell death in PCa cells may also
involve a caspase-independent pathway, we first determined whether caspase inhibition
would prevent the death of drug-treated PCS cells. Both low and high concentrations of
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Figure 6. Docetaxel (DTX) induces caspase-dependent death in PCS cells. A. Caspase3/7 and -2 activity assays in DTX-treated PCS cells in the presence and absence of the
pan caspase inhibitor Z-VAD-FMK and the caspase-2 inhibitor Ac-VDVAD-CHO
respectively. Cells were pre-treated 1 h prior to drug treatment. Activity was determined
by measuring the cleavage of the fluorogenic substrate Ac-DEVD-AMC for caspase-3/7
and Ac-VDYAD-AMC for caspase-2. Fold activation was determined by normalization
of the test sample to untreated controls. B. Immunoblotting analysis of PARP and
LEDGF/p75 cleavage in DTX-treated PCS cells in the presence and absence of Z-VADFMK.
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DTX reduced cell viability as measured by crystal violet staining (Fig. 7A). However,
this reduction was only partially abrogated in the presence of the caspase inhibitors ZVAD-FMK and Ac-VDVAD-CHO, suggesting that a caspase-independent pathway was
also activated by DTX. Similar results were observed in DU 145 and RWPE-2 cells (data
not shown). To confirm that the loss of viability measured in DTX-treated PC3 cells with
the crystal violet method was not merely the result of cell rounding and detachment
associated with mitotic arrest, we also measured cell viability using the MTT method,
with similar results (Fig. 7B). Consistent with these results, morphological analysis
revealed the presence of both rounded and dead cells after treatment with DTX for up to
48 h in the presence of caspase inhibitors (Fig. 7C). However, most cells treated with
TRAIL in the presence of caspase inhibitors were still attached and did not display
apoptotic morphology (Fig. 7C).

DTX-induced PC3 Cell Death Involves Lysosomal Membrane
Permeabilization
We evaluated the possibility that DTX might activate the lysosomal cell death pathway
concomitant with activation of the caspase-dependent pathway. The acridine orange (AO)
method was used to assess lysosomal membrane permeabilization (LMP) in PC3 cells
after treatment with 0.1 or 3.0 pM DTX for up to 48 h. Both concentrations of DTX
induced extensive AO leakage into the cytosol, producing a diffuse yellow color (Fig.
8A). This was visible mostly in detached cells and was not caspase-dependent since it
could not be inhibited by Z-VAD-FMK (Fig. 4A), Ac-VDVAD-CHO (data not shown),
or the combination of both inhibitors (data not shown). The attached cells still had intact
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Figure 6. Docetaxel (DTX) induces caspase-dependent death in PC3 cells. C. Flow
cytometric analysis of mitochondrial membrane potential (MMP), using the JC-1 method,
in PC3 cells treated with DTX in the presence and absence of Z-VAD-FMK for 48 h. A
representative of three independent experiments is shown. D. Cell cycle analysis of PC3
cells treated with DTX in the presence and absence of Z-VAD-FMK for 48 h. Flow
cytometric analysis of cells stained with propidium iodide was used to determine the
percentage of cells in SubGl and G2/M. Representative DNA histograms are shown.
Error bars in panels A and D represent the standard deviation of at least three
independent experiments done in triplicates (* p < 0.05, t-test).
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compared to untreated, t-test).
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lysosomes (as visualized by punctuated cytoplasmic red AO staining) but appeared to
undergo mitotic catastrophe, as evidenced by the presence of multinucleation (Fig. 8A).
LMP is typically associated with release and activation of cathepsins, particularly
cathepsins B, D and L [47,48]. To investigate the involvement of these cathepsins in
DTX induced PCS cytoxicity, we evaluated whether their inhibition attenuated cell death.
For these experiments, PCS cells were pre-incubated with cathepsin B inhibitor (CA74Me), cathepsin D inhibitor (pepstatin A), or cathepsin L inhibitor (Cathepsin L
inhibitor) prior to exposure to DTX. Inhibition of cathepsins D and L had no effect on
PCS cell viability in the presence of low and high doses of DTX. However, inhibition of
cathepsin B significantly increased cell viability (Fig. 8B).
To determine if cathepsin B is released from the lysosomes after treatment of PCS
cells with DTX, a cathepsin B activity assay was performed in which changes in the
intracellular localization of the activity of this protease were examined by fluorescence
microscopy. Cathepsin B activity was detected using the fluorogenic substrate Magic Red
MR-(RR)2. This substrate fluoresces once cleaved by cathepsin B. Untreated cells
displayed red fluorescence mostly localized to the lysosomes (Fig. 8C). However, cells
treated with 0.1 or 3 pM DTX for 36 h displayed diffuse red fluorescence, indicative of
cathepsin B activity in the cytosol, most likely resulting from LMP. In the presence of
cathepsin B inhibitor there was red fluorescence localized inside the lysosomes in the
majority of DTX-treated cells, consistent with attenuation of LMP during DTX-induced
cell death. The detection of this red fluorescence also indicated that the inhibitor did not
block completely cathepsin B activity.
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visualized on an Olympus 1X70 inverted microscope equipped with Hoffmann
Modulation Contrast.
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Figure 8. DTX induces lysosomal membrane permeabilization (LMP) in PC3 cells. A.
Determination of lysosomal integrity in PC3 cells treated with DTX for 24 hours in the
presence and absence of Z-VAD-FMK. Cells were exposed to acridine orange (AO) for
lysosome visualization under fluorescence microscopy. Untreated cells showed localized
granular red fluorescence corresponding to staining of intact lysosomes. Cells that
detached after treatment with DTX in the presence and absence of Z-VAD-FMK
displayed increased yellow fluorescence indicative of LMP. Most cells that remained
attached after treatment appeared to have intact lysosomes but exhibited multinucleation.
Hoescht staining was used to visualize nuclear morphology.
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Simultaneous Inhibition of Caspases and Cathepsin B Antagonizes
DTX-induced Cell Death
In light of the above results indicating attenuation of DTX-induced cell death by
inhibition of cathepsin B, we sought to explore whether blocking cathepsin B activity was
sufficient to delay LMP in DTX-treated PCS cells. Staining of PCS cells with AO after
exposure to DTX and cathepsin B inhibitor for 36 h revealed that while LMP was not as
prominent as observed in DTX-treated cells in the absence of inhibitor, there were still
yellow cells present, indicating that inhibition of cathepsin B did not confer full
protection against DTX-induced cell death (Fig. 9A, compare with Fig. 8A). Since
cathepsin B can induce nuclear fragmentation upon release from lysosomes [47], we also
examined the effects of cathepsin B inhibition on DNA fragmentation. Inhibition of
cathepsin B partially protected against DTX-induced DNA fragmentation, as inferred by
the reduction of the subGl cell population in cultures treated with cathepsin B inhibitor
(Fig. 9B). These findings were consistent with the partial protection conferred by
cathepsin B inhibitor against DTX-induced cytotoxicity (Fig. 8B).
To determine if both caspases and cathepsin B contribute to LMP, we treated PCS
cells with 0.1 or 3 pM DTX for 36 h in the presence of both Z-VAD-FMK and cathepsin
B inhibitor. Interestingly, LMP was markedly decreased in cells treated with both
inhibitors, as inferred by the reduction in the number of yellow cells (Figure 9C).
Furthermore, DTX-induced DNA fragmentation was abolished in the presence of both
inhibitors (Fig. 9D). We followed the survival of cells treated with DTX in the presence
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of both Z-VAD-FMK and cathepsin B inhibitor for up to 7 days and noticed that the
majority of cells survived as long as both inhibitors were added freshly to cell cultures
every 36 h (data not shown). Taken together, these results indicated that caspases and
cathepsins, particularly cathepsin B, play a concerted role during DTX-induced
cytotoxicity.

Overexpression of LEDGF/p75 Attenuates DTX-induced Cell Death
In light of a recent report suggesting that LEDGF/p75 promotes lysosomal
stabilization in response to cytotoxic drugs [27], we investigated whether its ectopic
expression in PC3 cells would antagonize DTX-induced cytotoxicity and LMP. For these
experiments, we generated cell lines stably overexpressing LEDGF/p75 (Fig. 10A).
Clones stably expressing LEDGF/p75 displayed increased resistance to 0.1 or 3 pM
DTX, when compared to clones transfected with empty pcDNA vector (Fig. 10B).
Interestingly, LEDGF/p75 expression did not attenuate TRAIL-induced cell death (Fig.
10B). Consistent with these results, ectopic expression of LEDGF/p75 was also observed
to protect RWPE-2 cells against DTX-induced cell death but not against TRAIL or STSinduced cell death (data not shown). Morphological analysis of stable transfectants
exposed to DTX for 48 h showed less cell rounding and death in cultures of PC3 cells
overexpressing LEDGF/p75 (Fig. 10C). Also, flow cytometric cell cycle analysis
revealed a reduction in the percentage of subGl cells in DTX-treated cultures, consistent
with a decrease in the levels of DNA fragmentation (Fig. 10D). However, overexpression
of LEDGF/p75 did not abrogate the ability of DTX to induce mitotic arrest, as indicated
by the increase in the G2/M fraction in cells treated with 0.1 or 3 pM DTX (Fig. 10D).

76

Hoechst
0.1 pM DTX
+ CBI

3 nM DTX
+ CBI

77

Figure 9. Simultaneous inhibition of caspases and cathepsin B attenuates DTX-induced
cell LMP and DNA fragmentation. A. PCS cell cultures treated with DTX for 36 hours in
the presence of cathepsin B inhibitor and stained with acridine orange showed less
detached yellow cells than cultures treated with DTX in the absence of inhibitor
(compare with Fig. 8A)
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Figure 9. Simultaneous inhibition of caspases and cathepsin B attenuates DTX-induced
cell LMP and DNA fragmentation. C. PC3 cell cultures treated with DTX for 36 hours in
the presence of both Z-VAD-FMK and cathepsin B inhibitor, and stained with acridine
orange, showed very few yellow detached cells, as compared with cultures treated with
DTX in the absence of inhibitors (see Fig. 8A).
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Figure 9. Simultaneous inhibition of caspases and cathepsin B attenuates DTX-induced
cell LMP and DNA fragmentation. D. Cell cycle analysis of PC3 cells treated with DTX
in the presence and absence of Z-VAD-FMK and cathepisn B inhibitor for 48 h. Flow
cytometric analysis of cells stained with propidium iodide was used to determine the
percentage of subGl cells. Representative DNA histograms are shown. Error bars
represent the standard deviation of at least three independent experiments done in
triplicates (* p < 0.05, t-test).
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We also investigated whether stable overexpression of LEDGF/p75 stabilized lysosomes
in PC3 cells treated with DTX for up to 48 h. Clones overexpressing LEDGF/p75 which
were exposed to DTX exhibited more attached cells and less detached cells or cells
undergoing apoptosis than cultures transfected with empty vector (Fig. 11). All the
attached cells overexpressing LEDGF/p75 and treated with DTX exhibited stable
lysosomes, as evidenced by the presence of cytoplasmic red speckles and absence of
yellow-colored cells. However, the majority of these attached cells displayed
multinucleation, suggesting that ectopic expression of LEDGF/p75 attenuates DTXinduced LMP and apoptosis but not mitotic catastrophe.

Discussion
Several recent studies have established that DTX induces tumor cell death
primarily through mitotic catastrophe and apoptosis [11-16]. However, the role of a
lysosomal pathway in DTX-induced cell death has not been thoroughly investigated.
DTX-induced apoptosis in melanoma and prostate cancer cells has been shown to involve
activation of caspases-2 and -3, and changes in MMP [14, 16], Mhaidat et al [14] showed
that changes in MMP were almost completely inhibited after caspase-2 knockdown,
suggesting that DTX-induced apoptosis is dependent on caspase-2 activation [14].
Hernandez-Vargas et al [15] reported that the coupling of mitotic catastrophe with
apoptosis occurs in breast cancer cells only at 0.1 pM (100 nM) concentrations, whereas
very low concentrations of 2-4 nM induce mitotic catastrophe followed by a late necrosis.
An earlier study by Schimming and colleagues [17] provided evidence that DTX is a
potent inducer of mitotic arrest, apoptosis, and necrotic-like tumor cell lysis with
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Figure 10 Overexpression of LEDGF/p75 attenuates DTX-induced cell death. A.
LEDGF/p75 expression in parental PCS cells, pools of PCS clones stably transfected with
empty pcDNA vector (Vec), or pcDNA-ledgfp75 (p75), analyzed by immunoblotting
(right panel) and RT-PCR. B. Stable overexpression of LEDGF/p75 attenuated DTXinduced cytotoxicity after 36 and 48 h of exposure to low and high concentrations of the
drug. Cell survival was determined by crystal violet staining. Data is representative of
three independent experiments. Error bars represent the standard deviation of at least
three independent experiments done in triplicates (* p < 0.05, t-test).
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Figure 10. Overexpression of LEDGF/p75 attenuates DTX-induced cell death. C.
Morphology of PC3 clones (Vec and p75) treated with DTX for 48 hours. Clones
overexpressing LEDGF/p75 showed less dead and detached cells than clones transfected
with empty vector.
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Figure 10. Overexpression of LEDGF/p75 attenuates DTX-induced cell death. D. Cell
cycle analysis of PCS clones (Vec, and p75) treated with DTX for 48 h. Flow cytometric
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Figure 11. Overexpression of LEDGF/p75 attenuates DTX-induced LMP. PC3 cell
clones (Vec and p75) were treated with DTX for up to 48 hours and stained with acridine
orange to visualize LMP. Clones stably transfected with empty vector (Vec) showed
increased LMP as indicated by minimal or absence of punctuated lysosomal red
fluorescence, associated with increased number of detached yellow cells. Clones
overexpressing LEDGF/p75 showed less cell detachment and increased lysosomal
stability after DTX treatment. These resistant clones displayed extensive multinucleation.
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proinflammatory properties in 15 syngeneic mouse xenografts. Consistent with these
previous findings, our present study demonstrates that DTX induced mitotic catastrophe
as well as apoptosis associated with caspase-2 and -3 activation, loss of MMP, and DNA
fragmentation in the HRPC cell line PC3. The loss of MMP and the DNA fragmentation
were largely caspase-dependent since they were inhibited by Z-VAD-FMK.
However, we noticed that although inhibition of caspases-2 and -3 with Ac
VDVAD-CHO and Z-VAD-FMK reduced DTX-induced cytotoxicity, it did not
completely block cell death, as assessed by viability assays, morphological visualization,
and analysis of LMP. These results indicated that DTX-induced cell death is not entirely
dependent on caspase activation and involves, in addition to mitotic catastrophe and
apoptosis, a caspase-independent pathway that involves LMP. LMP and cathepsin
activation are events associated with chemotherapy-induced cell death [47,48]. These
events occur during both caspase-dependent and independent cell death, and involves the
activation of cathepsins B, D, and L, [47,48]. These proteases contribute to cell death by
activating effectors such as mitochondria-associated proteins, caspases,
apoptosisinducing factor (AIF), or by directly cleaving nuclear and cytoplasmic factors
[47,48],
Our data suggest that DTX-induced caspase-independent cell death involves LMP
associated with cathepsin B activity. Cathepsins D and L do not appear to contribute
significantly to this process since their inhibition did not attenuate DTX-induced cell
death. These results are consistent with a report implicating LMP and activation of
cathepsin B, but not cathepsin D, in caspase independent cell death induced by the
microtubule stabilizing agents paclitaxel, epothilone B, and discodermolide in lung
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cancer cells [19]. The release of cathepsin B from lysosomes typically follows induction
of LMP by agents such as reactive oxygen species, fatty acids, and microtubule toxins
[47]. Cathepsin B itself can induce LMP, although the mechanisms are unknown [47].
Once released from the lysosomes, cathepsin B can induce both caspase-dependent and
independent cell death, as well as nuclear fragmentation [47]. Interestingly, our data
show that inhibition of cathepsin B alone is not sufficient to completely block DTXinduced LMP and DNA fragmentation. However, inhibition of both cathepsin B and
caspases led to a dramatic reduction of these events. These findings point to cathepsin B
as a key mediator of lysosome-mediated cell death induced by microtubule-stabilizing
drugs. They also suggest that DTX-induced cytotoxicity involves the concerted play of
caspases and cathepsin B. Several endogenous inhibitors of lysosome-mediated cell death
have been identified [47,48]. Among these, heat-shock protein (Hsp) 70 family members
and LEDGF/p75 have recently attracted attention due to their frequent overexpression in
tumors, and cytoprotective and chemoresistance properties. Daugaard et al [27] showed
that depletion of one protein of the Hsp70 family, Hsp70-2, triggers LMP and cathepsindependent cell death possibly through downregulation of LEDGF/p75. Transient siRNAmediated knockdown of LEDGF/p75 in HeLa, MCF-7, and U20S cells induced
lysosomal destabilization followed by caspase independent cell death [27].
Overexpression of ectopic LEDGF/p75 protected these cancer cells against the LMPinducing agents siramesine and doxorubicin [27].
Our data showed that ectopic overexpression of LEDGF/p75 attenuated DTXinduced cytotoxicity in PC3 cells but had no effect on TRAIL-induced cell death.
Overexpression of LEDGF/p75 in these cells attenuated both DNA fragmentation and
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LMP. Overexpression of LEDGF/p75 also attenuated DTX-induced death in RWPE-2
cells but was not effective against TRAIL and STS (data not shown). This selectivity in
the pro-survival function of LEDGF/p75 suggested that this protein could be an
endogenous inhibitor of cell death, caspase-dependent or independent, associated with
LMP, but not a general inhibitor of apoptosis. Interestingly, LEDGF/p75 overexpression
failed to prevent DTX-induced multinucleation, suggesting that DTX-induced mitotic
catastrophe is not coupled to lysosomal cell death. The mechanisms by which
LEDGF/p75 promotes lysosomal stability are presently unknown. Unlike HSP70,
LEDGF/p75 does not localize to lysosomal membranes [27]. There is a wealth of
evidence indicating that overexpression of LEDGF/p75 in tumor and non-tumor cells
confers protection against various stresses, including oxidative stress, heat stress, and
serum starvation [24-26,40,41]. There is also evidence that LEDGF/p75, acting as a
transcriptional coactivator, upregulates stress and antioxidant genes that protect cells
against reactive oxygen species (ROS) [40,41]. These ROS could damage lysosomal
membranes and induce LMP. It has been proposed that LEDGF/p75 activate stress and
antioxidant genes by specific binding to heat shock and stress elements in their promoter
regions [41]. Recent LEDGF/p75-DNA binding studies, however, have questioned the
sequence specificity of LEDGF/p75 binding to promoter regions [49]. Furthermore, gene
profiling analysis of cancer cells stably depleted of LEDGF/p75 have failed to reveal a
well-defined gene pathway regulated by this protein [reviewed in 37]. Interestingly, a
recent study showed that LEDGF/p75 physically interacts with the oncogenic
transcription factor menin and the MLL histone methyltransferase to activate cancer
associated genes and promote leukemic transformation [42]. This suggests that
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LEDGF/p75’s ability to promote tumor resistance to chemotherapy might be associated
with its capacity to form protein complexes required for transcriptional activation of
protective genes.
Conclusions
The results presented in this study underscore the ability of DTX to induce
concomitantly caspase-dependent and independent death pathways in prostate cancer
cells. Our data also point to LEDGF/p75 as a potential contributor to prostate cancer cell
resistance to DTX-induced LMP and cell death in vitro. The upregulation of stress and
antioxidant genes is emerging as a mechanism associated with tumor chemoresistance. It
remains to be investigated if LEDGF/p75 overexpression in human prostate tumors
contributes to the upregulation or activity of stress/redox genes associated with cancer
progression and chemoresistance. If this turns out to be the case, LEDGF/p75, its protein
interacting partners, and its target genes might become attractive candidates for molecular
targeting, in combination with DTX and other drugs, in the treatment of HRPC.
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Abstract

Background: Lens epithelium derived growth factor/p75 (LEDGF/p75) is a transcription
coactivator that protects mammalian cells from stress-induced death through the
transcriptional upregulation of stress proteins. Overexpression of LEDGF/p75 has been
identified in prostate cancer (PCa) cell lines and tissues. In addition, LEDGF/p75 has
been shown to protect cells from various environmental stressors. It is not clear whether
LEDGF/p75 is a general inhibitor of apoptosis, or if it selectively protects against stressinduced cell death. This study was designed to examine LEDGF/p75’s protective role
against oxidative stress, and to gain mechanistic insights into this protective role.
Methods: RWPE-2 cells stably overexpressing LEDGF/p75 were developed to
investigate its biological impact. Determination of cell death induced by tert-butyl
hydrogen peroxide (TBHP), tumor necrosis factor-related apoptosis inducing ligand
(TRAIL) and staurosporine (STS) was observed through a combination of viability,
morphological, and apoptosis assays. Kinetworks™ stress/heat shock protein screen was
utilized to identify potential target genes of LEDGF/p75. Immunobloting, luciferase
reporter assay and si-RNA-mediated knockdown experiments were conducted to
determine a correlation between LEDGF/p75 and the oxidoreductase ERp57.
Results: TBHP induced non-apoptotic cell death through the generation of ROS in
RWPE-2 cells. Overexpression of LEDGF/p75 protected against TBHP-induced cell
death but not against the classical apoptotic death inducers TRAIL and STS suggesting
that LEDGF/p75 pro-survival properties might be specific to ROS-induced cell death.
Kinetworks™ stress/heat shock protein screen was carried out to explore a possible
mechanism by which LEDGF/p75 promotes this resistance. We observed that
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overexpression of LEDGF/p75 led to upregulation of the thiol-oxidoreductase ERp57.
This upregulation was confirmed by immunoblotting, and luciferase reporter assays.
However, there was no evident correlation in the expression of the two proteins in panels
of PCa cell lines and tumor tissues.
Conclusion: Overexpression of LEDGF/p75 might selectively protect PCa cells against
stressors that induce ROS, possibly through upregulation of stress/redox genes such as
ERp57.

Keywords: LEDGF/p75; prostate cancer; ERp57; oxidative stress

106

Introduction
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and the
second leading cause of male cancer deaths in the U.S. (1). In 2008 it was estimated that
186,320 American men were diagnosed with PCa and 28,660 died because of the disease
(1). Multiple factors and signaling pathways have been associated with the development
of PCa. However, the triggers for initiation of this malignancy are still not completely
understood (2,3). Many factors such as age, race, diet, environmental carcinogens,
oxidative stress, and inflammatory diseases of the prostate have been linked to an
increase in PCa risk (2,4,5). Furthermore, there is considerable evidence suggesting that
oxidative stress contributes to the etiology and progression of the disease (2,5-7).
Oxidative stress is defined as a disturbance in the equilibrium between reactive
oxygen species (ROS) and detoxifying anti-oxidants. This balance is normally
maintained by intracellular antioxidants (vitamin C, vitamin E and selenium) and
antioxidant enzymes such as glutathione S-transferase (GST)-ti (7). Increased levels of
ROS lead to the damage of important cellular molecules, including lipids, proteins and
DNA, as well as increased expression of stress-regulated transcription factors involved in
neoplastic transformation (8-11). Recent studies have shown higher oxidative stress
within the epithelium of PCa patients than men without the disease (5). In addition, ROS
also participate in mechanisms associated with tumor metastasis and migration (12).
However, the molecular mechanisms by which tumor cells develop resistance to
oxidative stress-induced damage and cell death have not been fully elucidated.
Lens epithelium derived growth factor/p75 (LEDGF/p75), also known as
transcription co-activator p75 (TCP75), PC4 and SFRS1 interacting protein (PSIP), and
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dense fine speckled autoantigen of 70 kD (DFS70), is a stress-regulated survival protein
and transcriptional co-activator (13-15). The LEDGF/p75 gene is located on chromosome
9p22.2, a region of interest since it is a common target for a variety of human cancers
(16). LEDGF/p75 has been found to be upregulated in response to heat and oxidative
stress, and promotes resistance of mammalian cells to stress induced cell death (17-21). It
is presumed that the stress survival functions of LEDGF/p75 are associated with its
ability to transcriptionally activate stress genes via interaction with heat shock elements
(HSE) and stress response elements (STRE) in promoter regions. Genes known to be
transactivated by LEDGF/p75 are antioxidant protein 2 (AOP2/Prdx6), involucrin,
alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), Hsp27, and aBcrystallin (20,22-25).
LEDGF/p75 gene expression is upregulated in PCa cell lines and tissue (26).
Overexpression of LEDGF/p75 in MCF-7 breast cancer cells lead to their protection
against cell death induced by agents that trigger lysosomal membrane permeabilization
(27). In addition, recent work from our laboratory showed that overexpression of
LEDGF/p75 conferred a protective effect against docetaxel-induced cell death (Chapter
2). However, the mechanisms by which it confers resistance to oxidative stress and
chemotherapeutic agents are not well understood. The aim of this work is to establish that
LEDGF/p75 confers resistance to oxidative stress-induced cell death in PCa cells through
the attenuation of ROS and that the upregulation of the oxidoreductase ERp57 might be a
mechanistic event underlying this attenuation.
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Materials and Methods
Cell Lines, Antibodies, and Reagents
RWPE-2, RWPE-1, PCS, DU145, 22RV1, and LnCaP cell lines were obtained
from American Type Culture Collection (ATCC) and cultured according to
manufacturer’s recommendations. 55T and 4IT were obtained from AthenaES and
cultured according to manufacturer’s recommendations. Normal prostate epithelial PrEC
cells and normal prostate stromal PrSC cells were obtained from Clonetics-Biowhittaker
and cultured according to manufacturer’s Clonetics-Biowhittaker recommendations. The
following antibodies were used: anti-Lamin B goat polyclonal antibody C-20 (Santa Cruz
Biotechnology), mouse monoclonal anti-p-actin (Sigma-Aldrich), mouse monoclonal
anti-ERp57 (Stressgen) and horseradish peroxidase (HRP)-labeled secondary IgG
antibodies (Zymed). Human autoantibodies to LEDGF/p75 were a kind gift from Dr.
Edward Chan (University of Florida, Gainesville). Tert-butyl hydrogen peroxide (TBHP)
was purchased from Sigma. Recombinant human tumor necrosis factor related apoptosis
inducing ligand (TRAIL) and actinomycin D were purchased from R&D Systems.
Staurosporine (STS), and N-acetyl-Asp-Glu-Val-Asp-7-amino- 4-methylcoumarin (AcDEVD-AMC, fluorogenic caspase-3/7 substrate) were purchased from Axxora.

Induction of Cell Death
Cell death was induced by treatment with TBHP (150 pM), TRAIL/actinomycin
D (100 ng/ml each), or 4 pM STS for up to 24 h. Cells morphology was visualized on an
Olympus 1X70 microscope equipped with Hoffmann Modulation Contrast (Olympus
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American). Images were acquired using a digital Spot Imaging System (Diagnostic
Instruments).

Cell Viability Assays
Cells seeded in 96-well plates (3 x 104 cells per well) were treated with cytotoxic
drugs, washed with phosphate buffered saline (PBS), and fixed in 4% paraformaldehyde
for 1 h at 4°C. Cells were then washed three times with distilled water, and Accustain
Crystal Violet solution (Sigma-Aldrich) (1:4) was added to each well followed by
incubation for 20 minutes at room temperature. Plates were washed with distilled water to
remove excess dye and then dried at room temperature. Acetic acid (10% v/v) was added
to each well for 10 minutes and absorbance was measured at 570 nanometers (nm) using
a pQuant microplate reader (Bio-tek Instruments).

DAPI Staining
Cells were seeded (3 x 104) in 8-well Lab-Tek® Permanox® chamber slides
(Fisher Scientific) and treated after 24 h with the different cytotoxic drugs. Cells were
washed with PBS, fixed, and permeabilized with methanol/acetone (3:1 v/v) for 10
minutes at -20°C. The fixing solution was removed and the slides were incubated at room
temperature for 5-10 minutes for drying. Coverslips were mounted using VectaShield
containing DAPI (Vector Laboratories) and the edges were sealed with clear nail polish.
DAPI staining was visualized using and Olympus BX50 Fluorescent Microscope
(Olympus). Images were obtained using the Spot Imaging System (Diagnostic
Instruments).
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Measurement of ROS by Flow Cytometric Analysis
Generation of reactive oxygen species (ROS) were assessed based on the
intracellular oxidation of 2,,7,-dichlorodihydrofluorescein diacetate (DCFH-DA,
Invitrogen) to form the fluorescent compound 2’,7’-dicholorofluorescein (DCF). Cells
were seeded in a 6-well plate at a density of 3 x 105 cells per well and cultured for 24
hours. Treatment of cells with the drugs was done for up to 12 h. Then, DCFH-DA (0.5
pM) was added to the cells, followed by incubation for 20 minutes at 37°C. The cells
were washed with PBS (2X), and then resuspended in 0.5 mL of PBS. Fluorescence
intensity was determined by flow cytometry using the FACScalibur (BD Biosciences).

Caspase Activity Assays
Caspase activity assays were performed as described previously (28). Briefly,
cells were seeded in black, clear-bottomed 96-well plates (3 x 104 cells per well). At the
conclusion of treatment with cytotoxic drugs or inhibitors, cells were incubated with 50
pi of 3X caspase buffer [150 mM Hepes pH 7.4, 450 mM sodium chloride, 150 mM
potassium chloride, 30 mM magnesium chloride, 1.2 mM ethylene glycol-bis(2aminoethylether^MMA^A'-tetraacetic acid (EGTA), 30% sucrose, 10% CHAPS, and
1.5% NP-40], in the presence of 30 mM dithiothreitol (DTT), 3 mM
phenylmethanesulphonylfluoride (PMSF), and 75 pM of the fluorogenic peptide
substrates Ac-DEVD-AMC (caspase-3/7) or Ac-VDVAD-AMC (caspase-2) for 2 h at
37°C, followed by incubation at room temperature for 12 h. Absorbance was then read in
a FLX800 Microplate Fluorescent Reader (Bio-tek Instruments) at excitation of 360 nm
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and emission of 460 nm. Fold activity was determined by normalizing to one the
absorbance values for untreated cells.

Immunoblotting
Equal amounts of protein from whole cell lysates were separated by sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), blotted onto polyvinyl
difluoride (PVDF) membranes, and analyzed by immunoblotting as described previously
(21).

Generation of Cell Lines Stably Overexpressing LEDGF/p75
The LEDGF/p75 cDNA was previously cloned into the mammalian expression
vector pcDNA3.1+ (Invitrogen) (21). Both the pcDNA3.1+ empty vector and
pcDNA3.1+/LEDGF/p75 vector were transfected into RWPE-2 cells using the Fugene 6
method (Roche). Forty-eight hours post-transfection, cells were trypsinized and seeded
into 6-well plates. Selection of stable transfectants was achieved by adding G418 (Fisher
Scientific) to the cell cultures. Colonies were expanded and assayed for increased
expression of LEDGF/p75 by immunoblotting. Clones overexpressing LEDGF/p75 were
selected for further expansion and stored in liquid nitrogen.

Kinetworks™ Stress/Heat Shock Protein Screen
The Kinetworks™ Stress/Heat Shock Protein Screen (Kinexus Bioinformatics
Corporation) was used to quantify and comper the expression level of 25 stress and heat
shock proteins in whole cell lysates from RWPE-2 cells stably overexpressing
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LEDGF/p75 and cell stably transfected with empty pcDNA vector. Cell lysates were
prepared as instructed by Kinexus (29). The protein concentration on each lysate was
determined using a DC Protein Assay (BioRad) and 500 pg of each sample was prepared
for shipment according to Kinexus instructions. The final concentration of each lysate
was 1 mg/mL.

Immunohistochemistry
Immunohistochemistry was performed as described by Daniels et al. (26). Briefly,
human prostate cancer Histo™-Array slides (Imgenex) were fixed, deparaffinized,
rehydrated, and stained using the Biogenic i6000 auto stainer (Biogenex Corporation)
following the manufacturer’s standardized immunohistochemistry protocol.

Luciferase-Based Transcription Reporter Assays
RWPE-2 cells were seeded (2 x 104 per well) in 24-well plates. After 24 h, cells
were co-transfected using Minis TransYY® Prostate Kit as per manufacturer’s instruction
with 3 pg of the reporter vector (pGL3 basic, pGL3-Hsp27pr or pGL3-ERp57pr) and 2
pg of the expression vector (pcDNA3.1 or pcDNA/LEDGF/p75). At 48 h
posttransfection, cells were lysed with IX passive lysis buffer (Promega) and luciferase
assays were done using the Luciferase Assay System (Promega). The assays were done in
opaque luminometer compatible microplates and relative light units were obtained in a
MicroLumatPlus Lb 96V luminometer (Berthold Tech). Luciferase values were
normalized to the amount of protein in each sample and the fold induction was calculated
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by normalizing to the luciferase activity in lysates from cells co-transfected with the
empty vectors and the reporter vectors.

LEDGF/p75 knockdown
PC3 and RWPE-2 cells (1 x 106) were centrifuged in 1.5mL tubes at 5,000 rpm
for 2 minutes. The supernatant was removed and the cells were resuspended in 100 pL of
Amaxa® nucleofection solution V and 20 pM of siRNA duplexes added when needed.
LEDGF/p75 siRNAs (LI and L3) and the scramble II siRNA (SDII, negative control)
were designed as described by Maertens et al. (30) with LI knocking down both
LEDGF/75 and its spliced variant LEDGF/p52, and L3 knocking down LEDGF/p75 and
were synthesized by IDT Technologies . Lamin A/C (L A/C) control siRNA was
designed using the Qiagen website. LI: 5,CAGCCCUGUCCUUCAGAGATT3,,
3,TTGUCGGGACAGGAAGUCUCU5’; L3: 5’AGACAGCAUGAGGAAGCGATT3’,
3’TTUCUGUCGUACIJCCUUCGCU5’; SDII: S’GCGCGCUUUGUAGGAUUCGTTS’,
3’TTCGCGCGAAACAUCCUAAGC5’; and lamin A/C:
5,CUGGACUUCCAGAAGAACA3\ 3,UGUUCUUCUGGAAGUCCAG5’. The cell
suspension was transferred to a cuvette and the nucleofection was performed using the
program T-13 using the Amaxa® Nucleofector®. The cell suspension was then
transferred to a 1.5 mL tube that contained 500 pL of RMPI and incubated at 37°C for 20
minutes. After the incubation, cells were seeded at approximately 3 x 104 cells per well in
6-well plates and lysates were collected 4 days later.
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Results
TBHP-induces Non-apoptotic Cell Death
To determine if TBHP-induced cytotoxicity in PCa cells occurs via a nonapoptotic process, we first examined cell viability and morphology in RWPE-2 cells after
treatment with 150 pM of TBHP, 100 ng/mL of TRAIL/Act.D and 4 pM of STS for up to
24 h. All three cytotoxic drugs reduced cell viability as measured by crystal violet
staining (Figure 12 A). Morphological analysis revealed the presence of classical
apoptotic hallmarks such as blebbing and nuclear condensation and fragmentation in cells
treated with TRAIL/Act.D and STS, while cells treated with TBHP showed necrotic-like
morphology that included the classical swelling and condensed nuclei without
fragmentation (Figure 12B and C).
To further confirm the non-apoptotic cell death induced by TBHP, caspase 3/7
activity assays and immunobloting analysis were performed. Gradual activation of
caspase 3/7 was observed in cells treated with TRAIL/Act.D and STS for up to 24 h,
whereas TBHP-induced cell death showed no caspase 3/7 activation (Figure 12D). An
additional marker for apoptosis, cleavage of Lamin B, which is observed in apoptotic cell
death but not in necrosis (31,32), was used. Cleavage of Lamin B into its signature 45
kDa apoptotic fragment was observed in cells treated with TRAIL/Act.D and STS, but
not in cells treated with TBHP (Figure 12E).
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Figure 12. TBHP induces cell death via a non-apoptotic pathway. A. Percentage of
surviving RWPE-2 cells treated with 150 pM TBHP, 100 ng/mL TRAIL/Act.D or 4 pM
STS. Cell viability was determined by crystal violet staining. Absorbance was measured
at 570 nm and the values were normalized against those of untreated cells, which were
assumed to be 100% viable. Errors bars represent the standard deviation of at least three
independent experiments done in triplicate. B. Cellular morphology of RWPE-2 cells
treated with TBHP, TRAIL/Act.D and STS as in A. for 12 h. Cell morphology visualized
by Hoffman modulation microscopy. C. Nuclear morphology of RWPE-2 cells treated
with TBHP, TRAIL/Act.D and STS as in A. for 12 h. Nuclear morphology as visualized
by DAPI staining under fluorescent microscopy. Morphological analysis was done by Dr.
Tracy R. Daniels, a former grad student in Casiano’s lab.
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Figure 12. TBHP induced cell death via a non-apoptotic pathway. D. Detection of
caspase 3/7 activity by fluorometric assay in RWPE-2 cells treated with 150 pM TBHP,
100 ng/mL TRAIL/Act.D or 4 pM STS for the indicated time points, then incubated with
the Ac-DEVD-AMC substrate for 2 h. Fluorescence intensity (excitation 360
nM.emission 460 nM) was read using the FLx800 fluorescence microplate reader. Fold
activation was calculated as the ration of treated cells versus untreated cells. The graph
represents the average of 3 independent experiments performed in triplicates. E. Caspase
activity determined by immunoblotting analysis of the known caspase substrate Lamin B.
RWPE-2 cells were treated as in C. A goat polyclonal Lamin B antibody was used.
Immunoblotting was done by Dr. Tracy R. Daniels, a former grad student in Casiano’s
lab
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TBHP-induced Cell Death Increases ROS Production in RWPE-2
Cells
To detect and confirm the presence of ROS in RWPE-2 cells following treatment
with TBHP, DCFH-DA was added to cells after exposure to the cytotoxic drugs for 6 h.
RWPE-2 cells exposed to TBHP showed an increase in oxidation of DCFH-DA, while
exposure to TRAIL/Act.D or STS did not show an increase in ROS production (Figure 13
A. and B.).

LEDGF/p75 Attenuates TBHP-induced Cell Death
It was recently observed that hydrogen peroxide induced lysosomal alterations in
PC 12 cells (33). Also, LEDGF/p75 promotes lysosomal stabilization in response to
cytotoxic drugs (27) throught the possible attenuation of ROS (unpublished data). We
investigated whether ectopic expression of LEDGF/p75 in RWPE-2 cells would
antagonize TBHP-induced cytotoxicity. For these experiments, we generated cell lines
stably overexpressing LEDGF/p75 (Figure 14A). Clones stably overexpressing
LEDGF/p75 displayed a significant attenuation of cell death induced by TBHP when
compared to empty vector (Figure 14B). Interestingly, LEDGF/p75 expression did not
attenuate TRAIL/Act.D or STS induced cell death (Figure 14C and D).
Consistent with these findings, morphological analysis of LEDGF/p75 stable
transfectants exposed to TBHP for up to 24 h showed a relatively normal cellular
morphology (Figure 14E). Stable empty vector transfectants show the classical necrotic
swelling, providing evidence that LEDGF/p75 protects cells selectively against oxidantinduced cell death.
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Figure 13. Detection of levels of ROS in RWPE-2 cells. RWPE-2 cells were treated with
A. 150 jaM TBHP, and 150 jaM TBHP + 3 mM DTT; or B. 100 ng/mL TRAIL/Act.D or
4 jaM STS for the indicated time points. Cells were incubated with DCFH-DA, washed in
PBS, trypsinized, and pelleted. The pellet was washed with PBS (2X) and resuspended in
0.5 mL of PBS. Fluorescence intensity was determined using FACS analysis.
Representative of one experiment.
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LEDGF 8

LEDGF 12

Figure 14 Overexpression of LEDGF/p75 in RWPE-2 cells confers resistance to cell
death induced by TBHP but not TRAIL and STS. A. Stable overexpression of
LEDGF/p75 is RWPE-2 clones 8 and 12 detected by immunoblot analysis. Crystal violet
viability assays. B. 150 mM TBHP for 6 h and a 18 h recovery period. C. 100 ng/mL
TRAIL/Act.D for 6 h and a 18 h recovery period. D. 4 mM STS for 6 h and a 18 h
recovery period. Each graph represents the average of at least 3 independent experiments
performed in triplicates. All experiments in this figure were done by Dr. Tracy R.
Daniels, a former grad student in Casiano’s lab
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Figure 14. E. Morphological analysis of RWPE-2 cells. RWPE-2 cells were treated with
TBHP and were visualized by Hoffman modulation microscopy. Parental RWPE-2 cells
transfected with empty vector, and cells stably overexpressing LEDGF/p75 were treated
for 6 h with 150 pM TBHP. Morphological analysis was done by Dr. Tracy R. Daniels, a
former grad student in Casiano’s lab
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Overexpression of LEDGF/p75 Reduces ROS Production
To determine whether LEDGF/p75-induced protection against oxidant-induced
cell death is associated with decreased ROS generation, a DCFH-DA oxidation analysis
was done with cells stably overexpressing this protein. It was observed that the parental
cells show more oxidation of DCFH-DA when compared to RWPE-2 cells
overexpressing LEDGF/p75 (Figure 15). These results suggested that LEDGF/p75
overexpression reduces the endogenous levels of ROS, which could be associated with its
protective effects.

Overexpression of LEDGF/p75 Upregulates the Oxidoreductase
ERp57
In light of these results and the documented role of LEDGF/p75 as a transcription co
activator that promotes protection of mammalian cells from stress-induced cell death
through the transcriptional upregulation of stress response proteins, we performed a stress
protein profiling to identify proteins that could be upregulated by LEDGF/p75
overexpression. Lysates of RWPE-2 cells stably overexpressing LEDGF/p75, as well as
clones transfected with empty vector, were sent to Kinexus Bioinformatics Corporation
(Vancouver, Canada) for a Kinetworks™ protein profiling. Lysates were probed for the
quantitative expression of 25 known heat shock and stress related proteins using validated
commercial antibodies (Kinetworks™ KHSP-1.0 screen). Proteins profiled in the screen
included those listed in Table I. The empty vector clone was used to determine the basal
expression level. The data is presented as a fold increase or decrease in expression as
compared to empty vector. Of the 25 proteins analyzed, only 3 showed an upregulation of
more than 2 fold (Table I). ERp57 showed the highest upregulation with a 33.55 fold
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Detection of endogenous levels of ROS in RWPE-2 cells stably
Figure 15.
overexpressing LEDGF/p75. Analysis of ROS levels in parental RWPE-2, RWPE-2 cells
overexpressing LEDGF/p75 and RWPE-2 cells in the presence of the antioxidant DTI.
As described in Figure 13. Flow cytometry analysis was done by Dr. Tracy R. Daniels, a
former grad student in Casiano’s lab
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increase, followed by Hsp90 with a 4.54 fold increase, and Hop with a 3.17 fold increase
(Figure 16A).
To confirm the results of the Kinetworks™ KHSP-1.0 screen, we chose the two
proteins with the highest fold upregulation and tested them with our own immunoblot
analysis. Upregulation of ERp57 was observed in cells overexpressing LEDGF/p75,
when compared to the parental cell line as well as the empty vector clone (Figure 16B).
The expression levels of Hsp90 did not appear to change. These results suggested that
upregulation of the oxidoreductase ERp57 could be part of the mechanism by which
LEDGF/p75 protects from oxidative stress induced cell death.

LEDGF/p75 Transactivates the ERp57 Promoter
To determine if LEDGF/p75 transcriptionally regulates ERp57, a luciferase
transcription reporter analysis was performed. RWPE-2 cells co-transfected with the
ERp57 promoter (cloned in pGL3 vector) and pcDNA/LEDGF/p75 showed a significant
increase in the luciferase activity, when compared to cells co-transfected with empty
pcDNA and the x>GL?>-ERp57pr (Figure 17A). As a positive control, the promoter of a
stress protein known to be transcriptionally activated by LEDGF/p75 (Hsp27) was used,
with a significant increase in its transcriptional activity (Figure 17B). Together these
results suggested that LEDGF/p75 transactivates the ERp57 promoter.
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Table 1. List of proteins included in the Kinetworks™ Stress/Heat Shock
Protein Screen
No.

Abbreviation

1
2
3

APG1
APG2
COX-2

4
5
6
7
8

9
10
11
12
13
14
15
16
17
18
19
20

21
22
23
24
25

Full Name of Protein

APG1
APG2

Fold

nc
nc

Cyclo-oxygenase 2
Eukaryotic translation initiation factor 2a
ERp57
ER protein 57
ERp72
ER protein 72
GROEL
GroEL
Glucose regulated protein 75
GRP75
Glucose regulated protein 78
GRP78
GRP94
Glucose regulated protein 94
hHR23B
Human RAD23 homolog B
HIP
Hsp70/Hsc70 interacting protein
Heme oxygenase 1
HO-1
HO-2
Heme oxygenase 2
HSC70
heat shock 70 protein 8
HSF4
Heat shock transcription factor 4
Heat shock 25 protein
HSP25
DnaJ (HSP40) homolog
HSP40
HSP47
Heat shock protein 47
HSP60
Heat shock protein 60 (chaperonin)
Heat
shock protein 70
HSP70
HSP90a
Heat shock protein 90, alpha
Heat shock protein 105
HSP105
HSPBP1
Hsp70 binding protein 1
STI1/HQP-p60 Stress inducible protein 1

elF2 a
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Figure 16 Kinetworks™ multi-immunoblotting analysis (KHSP1.0). A. Vector alone
transfected cells and cells stably overexpressing LEDGF/p75 were individually
analyzed.. B. Untreated RWPE-2 parental cells, cells stably transfected with vector
alone, and cells overexpressing LEDGF/p75 were tested for upregulation of ERp57 and
Hsp90 to confirm Kinetworks™ multi-immunoblotting analysis. Immunoblotting was
done by Dr. Tracy R. Daniels, a former grad student in Casiano’s lab
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LEDGF/p75 and ERp57 Expression do not Appear to Correlate in PCa
Cells and Tissue
Since our data suggested that LEDGF/p75 transactivates the ERp57 promoter, we
wanted to determine if the expression of both proteins correlate in PCa cell lines and
tissue. For this experiment we examined a panel of prostate cell lines (PrEC, PrSC and
RWPE-1), BHP (55T), and PCa cell lines (RWPE-2, PC3, DU145, LnCaP, 22RV1,
MDA, and 4 IT) to observe if the expression levels of LEDGF/p75 paralleled those of
ERp57. Interestingly, there was no evident correlation in the expression of both proteins
(Figure ISA). For instance, LEDGF/p75 is expressed at relatively low levels in PrEC,
PrSC, and MDA cell lines, whereas ERp57 was expressed at relatively high levels in all
cell lines tested, particularly in the normal PrEC cell lines.Consistent with these results,
an immunohistochemical analysis using Imgenex PCa tissue microarray (TMA) showed
no correlation of LEDGF/p75 and ERp57 expression at the tissue level (Figure 18B).
We also investigated the expression of ERp57 in two PCa cell lines (PCS and
RWPE-2) with LEDGF/p75 transient siRNA-mediated knockdown (LI: targeting
LEDGF/p75 and p52, and L3: targeting LEDGF/p75). Consistent with the findings in
Figures 18A and B no downregulation of ERp57 was observed when LEDGF/p75 was
knocked down (Figure 18C). Taken together, these results indicate that even though
overexpression of LEDGF/p75 upregulates ERp57 and transactivates the ERp57
promoter, LEDGF/p75 might not be the main transcription factor involved in ERp57
transcription. However, LEDGF/p75 might be part of the transcription complex involved
in the activation of the ERp57 gene.
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Figure 17. Luciferase based transcription reporter assay. A. RWPE-2 cells co-transfected
with pGL3/ERp57 and pcDNA empty vector or pGL3/ERp57 and pcDNA/p75 were
analyzed using a luciferase based assay. B. RWPE-2 cells co-transfected with
pGL3/Hsp27 and pcDNA empty vector or pGL3/Hsp27 and pcDNA/p75 were analyzed
using a luciferase based assay. *(p<0.05)
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Figure 18. Correlation between LEDGF/p75 and ERp57 expression in PCa cell lines and
tissue. A. Immunoblot analysis of LEDGF/p75 and ERp57 in a panel of normal prostate
cells (PrEC, PrSC and RWPE-1), BHP (55T), and PCa cell lines (RWPE-2, PC3, DU 145,
LnCaP, MDA, 41T and 22RV1) was done to compare protein expression. B. Imgenex
PCa tissue array analysis of LEDGF/p75 and ERp57 expression. A representative normal
prostate tissue and PCa tissue from the array are shown.
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Figure 18. Correlation between LEDGF/p75 and ERp57 expression in PCa cell lines and
tissue. C. Analysis of ERp57 expression in PC3 and RWPE-2 cells with LEDGF/p75
knockdown (LI and L3) five days after Amaxa nucleofection. LI (oligo knocking down
LEDGF/p75 and p52) and L3 (oligo knocking down LEDGF/p75), as well as the controls
Lamin A/C and scramble duplex II were nucleofected using the Amaxa nucleofection
reagent. Five days after nucleofection cell lysates were collected and an immunoblot
analysis of ERp57 expression was conducted.
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Discussion
LEDGF/p75 is a known survival factor, as well as a transcription co-activator, in
various types of cancer cells. In this study we have demonstrated that overexpression of
LEDGF/p75 attenuates cell death induced by oxidative stress in the HRPC cell line
RWPE-2. It appears that this attenuation of cell death could be related to LEDGF/p75’s
ability to reduce the levels of ROS induced by TBHP. In addition, the mechanism
underlying this protection might involve the transactivation of stress response proteins by
LEDGF/p75, specifically the oxidoreductase ERp57.
Previous studies in LECs and Cos-7 cells show that overexpression of
LEDGF/p75, through the transactivation of AOP2, acquired resistance to H202-induced
cell death (23). This transactivation occurred through the binding of LEDGF/p75 to the
HSE or STRE in the AOP2 promoter (23,34). In addition Matsui et al. observed that, in
retinal pigment epithelial (RPE) cells, overexpression of LEDGF/p75 protected against
H2G2-induced cell death through the transactivation of the heat shock protein Hsp27.
Recently, our group detected autoantibodies against LEDGF/p75 in PCa patients,
as well as observed overexpression of the protein in PCa cell lines and tumor tissues (26).
Our data (Chapter 2) suggests that LEDGF/p75 attenuated cell death in PCa cells after
DTX treatment. We were able to show that overexpression of LEDGF/p75 decreased the
lysosomal membrane permeabilization when cells were treated with docetaxel (DTX), the
drug of choice for HRPC. Recently, Daugaard et al. observed that overexpression of
LEDGF/p75 in MCF-7 cells protected against various stimuli that triggered lysosomal
membrane permeabilization (27). Furthermore, they showed that knockdown of
LEDGF/p75 in HeLa cells decreased cell viability and induced a cathepsin dependent cell
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death (27). This study supports our previous findings on LEDGF/p75’s protective effect
through the stabilization of the lysosomes. Unpublished data from our group shows that
DTX-induced death elevates the intracellular levels of ROS. These studies suggest that
LEDGF/p75 protects PCa cells from DTX-induced death through the decrease on
intracellular levels of ROS. Further studies will have to prove that DTX-induced
lysosomal destabilization is due to the increase in ROS. This suggested mechanism is
supported by various observations that state that ROS levels increase in the presence of
DTX. Geng et al. observed that after 24 h of treatment with DTX, in the hepatocellular
carcinoma cell line SMMC-7721, the levels of ROS increased almost 2 times more than
the control (35,36). In the human leukemic cell line HL-60, a six fold increase was
observed after 24 h of DTX treatment at low concentrations. Lastly, Mizumachi et al.
observed ROS production in the laryngeal cancer cell line F[Ep2 after 24 h of treatment
with low doses of DTX. In addition, a DTX-resistant cell line, DRHEp2, was generated
and it was discovered that the resistance was acquired through the increase of FoATPase, which led to diminish DTX-induced ROS generation (37).
Converging evidence over the past decade has linked oxidative stress with
lysosomal permeabilization (33,38). Brunk et al. discussed that under normal conditions
the cell’s antioxidant defense system protects against most oxidative events. However, if
this protective shield is overwhelmed, H2O2 diffuses into the lysosomes causing
peroxidation of the lysosomal membrane which leads to the leakage of the lysosomes and
release of cathepsins (38). We could speculate that LEDGF/p75 protects PCa cells from
DTX and TBHP-induced cell death through the transactivation of stress proteins that
reduce the levels of intracellular ROS.
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The present study demonstrated through a Kinetworks™ Stress/Heat Shock
Protein Screen that overexpression of LEDGF/p75 in RWPE-2 cells induced upregulation
of the oxidoreductase ERp57. ERp57 is a member of the protein disulfide isomerase
(PDI) family, mainly found in the endoplasmic reticulum (ER) (39,40). The overall
sequence homology between ERp57 and PDI is of 33%, making it the closest known
homologue (39). Oxidoreductases are characterized by a functional CXXC motif, that
shares structural homology to thioredoxins, for catalysis of thiol-disulfide exchange
reactions (40,41). These reactions lead to the oxidation, reduction, or isomerization of
substrate cysteines (42). The two active site cysteines are found either in the oxidized or
reduced state; the oxidized form determines the function of the enzyme as an oxidase,
whereas the reduced form allows it to act as a reductase and/or an isomerase (42). ERp57
has also been found to be a component of the calnexin (CNX)/calreticulin (CRT)
chaperone system. This system promotes the folding and quality control of glycoproteins
in the ER (43). In addition, ERp57 is an important component of the major
histocompatibility omplex (MHC) class I peptide loading complex (44,45).
To confirm the results obtained from the protein screen, we were able to
demonstrate that LEDGF/p75 transactivates ERp57 promoter. Although no correlation
between the expression of LEDGF/p75 and ERp57 could be observed in a panel of PCa
cell lines, as well as tumor tissues, we cannot rule out that LEDGF/p75 might be a co
activator of ERp57. This suggested that other transcription factors might be involved in
the transactivation of ERp57. Another possibility is that transient knockdown of
LEDGF/p75 is not enough to observe a change in ERp57 expression. It is possible that
minute amounts of LEDGF/p75 might be enough to transactivate ERp57.
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Various groups have shown that overexpression of ERp57 has protective effects
against different insults. Grillo et al. observed that overexpression of ERp57 led to a
marked protective effect against toxicity induced by ROS in HeLa cells (46). ERp57
might be a target gene of LEDGF/p75 that reduces the levels of ROS in RWPE-2 cells
and attenuates oxidative stress-induced death.
In conclusion, this work provides further evidence that LEDGF/p75 is a survival
protein that transactivates stress related genes to protect PCa cells from oxidative stress.
These genes might include the oxidoreductase ERp57 which has been observed to protect
cells against oxidative stress. It is possible that while LEDGF/p75 contributes to ERp57
transactivation it may not be the main transcription factor involved in this event. Further
studies need to be performed to better understand the relationship between LEDGF/p75
and ERp57, and to assess if ERp57’s role in HRPC involves the reduction of intracellular
ROS induced by the tumor microenvironment. LEDGF/p75 and ERp57 might be
components of the mechanism of resistance against chemotherapy and oxidative damage
in cancer cells and could represent novel therapeutic targets in PCa.
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CHAPTER FOUR
RESULTS IN PROGRESS NOT INCLUDED IN PUBLICATIONS
Introduction
The ability to restore sensitivity to cell death in cancer cells is a crucial
determinant in the development of novel, effective treatment choices. Designing new
therapeutic strategies requires understanding the biological mechanisms which promote
tumor cell proliferation and survival (295). LEDGF/p75 is a known survival protein that
has been linked to attenuation of cell death induced by DTX and oxidative stress (Chapter
2 and 3). This attenuation might be related to the protein’s ability to upregulate stress
related proteins. One such protein is the oxidoreductase ERp57, implicated in attenuation
of cell death induced by oxidative stress in various systems (296). As discussed in
Chapters 2 and 3 we observed that overexpression of LEDGF/p75 in HRPC cell lines
increased resistance to DTX and TBHP but not to TRAIL and STS. We demonstrated
that TBHP but not TRAIL and STS induced ROS generation. It was therefore important
to also demonstrate that DTX-induced cell death is associated with ROS generation, and
to investigate if downregulation of the expression of LEDGF/p75 or ERp57 might
sensitize HRPC cells to DTX-induced death.
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Materials and Methods
ERp57 Knockdown
PC3 cells (2 x 104 per well) were seeded in a 24-well plate. The next day the cells
were transfected with using the siQUEST (Minis). Briefly, 5 pL of siQUEST reagent and
200 pL of RMPI without serum were added in a 1.5 mL tube and vortexed. Afterwards
20 pM of the oligo (02 or 03) were added and the reaction was mixed by pipetting up
and down. After incubating the solution for 20 minutes at room temperature, 50 pL of the
solution were added to four wells in the 24-well plate. Three days after transfection, the
cells were treated with either 0.01 pM or 0.1 pM of DTX and analyzed by crystal violate
viability assay for up to 72 hours.

Results
DTX-induced Death in PC3 Cells Increases the Intracellular Levels of
ROS
As discussed in Chapters 2 and 3, LEDGF/p75 attenuated cell death induced by
DTX and TBHP, but not TRAIL and STS. We also observed that TBHP, but not TRAIL
and STS increased the intracellular levels of ROS. To better understand the mechanism
by which LEDGF/p75 protects cells from DTX-induced death we examined if DTX
increased the intracellular levels of ROS. We show that low and high concentrations of
DTX (0.1 pM and 3 pM) increase the intracellular levels of ROS in PC3 cells (Figure
19).
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Transient Knockdown of LEDGF/p75 does not Sensitize PCS Cells
Growing in Monolayer to DTX-induced Cell Death
Recent studies observed that depletion of LEDGF/p75, by transient transfection using
siRNA oligos, decreased density of Hela, MCF-7 and U20S cell cultures 4 days after
transfection (280). The phenotype that was observed was of detached and rounded up
cells. Since our data suggested that overexpression of LEDGF/p75 attenuated cell death
induced by DTX and oxidative stress and therefore could be a potential target for therapy,
we decided to study if LEDGF/p75 knockdown would affect the growth of the HRPC cell
line PCS. PCS cells were transiently nucleofected with siRNA oligos against LEDGF/p75
(Figure 18 in Chapter 3) and viability was observed 5 days after nucleofection. We were
not able to observe a change in PCS cell density after knockdown of LEDGF/p75 (Figure
20). However, to determine if knockdown may lead to cell sensitization to drug-induced
cell death we decided to treat the cells with relatively low concentration of DTX. Three
days after nucleofection, PCS cells were treated with 0.1 pM of DTX and viability was
assessed up to 48 hours. Sensitization to DTX-induced cell death was not observed after
depletion of LEDGF/p75 (Figure 21). Further experiments might utilize lower
concentrations of DTX.
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Figure 19. Detection of endogenous levels of ROS in PC3 cells treated with DTX.
Analysis of ROS levels in PC3 cells treated with low (0.01 mM) and high (3.0 mM)
concentrations of DTX for 48 h. As described in Figure 13. One experiment
representative of three independent experiments.
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Figure 20. Depletion of LEDGF/p75 does not induce death of PC3 cells. PC3 cells were
transiently nucleofected (Amaxa) with siRNA oligos against LEDGF/p75 (LI and L3
described in Chapter 3, Figure 18). Viability was obtained, using the crystal violet assay,
up to 5 days after nucleofection. Error bars represent the standard deviation of at least
three independent experiments done in triplicates.
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Transient Knockdown of ERp57 does not Sensitize PC3 Cells to
DTX-induced Death
We also decided to determine if transient knockdown of ERp57 might lead to
sensitization to DTX-induced cell death. Transient transfection of two ERp57 siRNA
oligos (02 and 03) was performed and viability was observed up to 5 days after
transfection. Complete knockdown was observed with oligo 3 three days after
transfection, whereas oligo 2 showed almost 75% knockdown three days after
transfection (Figure 22). Our data suggests that depletion of ERp57 does not decrease cell
density in PC3 cells (Figure 23). To observe if a stressor was needed to observe
sensitization to cell death, PC3 cells depleted of ERp57 were treated with low doses
(A.0.01 pM and B. 0.1 pM) of DTX after 3 days of transfection and cell viability was
monitored up to 72 hours. Depletion of ERp57 did not sensitize PC3 cells to DTXinduced cell death (Figure 24).
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Figure 21. Depletion of LEDGF/p75 does not sensitize PCS cells to DTX-induced cell
death. Viability was assessed in PCS cells transiently nucleofected with LEDGF/p75
siRNA oligos (LI and L3) using crystal violet 3 days after nucleofection cells were
treated for up to 48 hours with 0.1 pM of DTX treatment. Error bars represent the
standard deviation of at least three independent experiments done in triplicates.
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Figure 22. Transient knockdown of ERp57 in PC3 cells. PCS cells were transiently
transfected with siRNA oligos for ERp57 (oligo 2 and oligo 3). Lysates were collected 3
and 5 days after transfection and immunoblotting was done to observe if complete or
partial knockdown was obtained.
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Figure 23. Depletion of ERp57 does not induce death of PCS cells. PCS cells were
transiently transfected with siRNA oligos against ERp57 (02 and 03). Viability was
obtained, using the crystal violet assay, from day 4 to day 6 after transfection. Error bars
represent the standard deviation of two independent experiments done in duplicates.
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Figure 24. Depletion of ERp57 does not sensitize PCS cells to DTX-induced cell death.
Viability was assessed in PCS cells transiently transfected with ERp57 siRNA oligos (02
and 03) using crystal violet, 3 days after nucleofection cells were treated for up to 48
hours with DTX (A. 0.01 pM and B. 0.1 pM). Error bars represent the standard deviation
of two independent experiments done in duplicates.
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Discussion
We were able to show that DTX-induced death increased the intracellular levels
of ROS in PC3 cells. This observation is the basis for supporting our hypothesis that
LEDGF/p75 attenuates cell death induced by DTX by decreasing the level of ROS.
Future studies will need to determine whether overexpression of LEDGF/p75 or ERp57
might decrease the intracellular levels of ROS induced by DTX. In addition, we will need
to determine if knockdown of LEDGF/p75 or ERp57 further increases DTX-induced
ROS.
Our previous work (Chapter 2 and 3) suggested that LEDGF/p75 or ERp57 might
be potential candidates for targeted therapy in PCa. Although there is evidence in the
literature to suggest that depletion of LEDGF/p75 decreases the viability of the cells
(280), in the HRPC cell line PC3 this phenomenon was not observed. The same result
was obtained when PC3 cells were depleted of ERp57.However, it has to be noted that
this was done in an in vitro environment in cells growing in monolayer and in the
presence of 10% serum. It is possible that if these experiments were to be done in cells
growing in a semi-solid medium, under stress conditions (serum starvation or utilizing
other cytotoxic drugs), or in an in vivo model the results might be different.
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CHAPTER FIVE
DISCUSSION
Role of Oxidative Stress in PCa
Over the last decade an association between PCa risk and oxidative stress has
been recognized. Epidemiological, experimental, and clinical studies have implicated
oxidative stress in the development and progression of the disease (297). Oxidative stress
can be defined as a disturbance in the equilibrium between ROS and detoxifying agents.
This balance is usually maintained by intracellular antioxidants (vitamin c, vitamin E and
selenium) and antioxidant enzymes (298). Common ROS include hydrogen peroxide,
superoxide ions and hydroxyl anions which directly damage DNA, and indirectly cause
lipid peroxidation (299). In addition, ROS react with DNA to form oxidative DNA
adducts which have been associated with mutagenesis and carcinogenesis (299).
Furthermore, ROS can also increase the expression of c-jun and c-fos, transcription
factors involved in neoplastic transformation (300).
It has been hypothesized that PIA is a pre-malignant condition, localized close to
PIN lesions and PCa has been associated with oxidative stress (84). PIA applies to focal
atrophic lesions associated with chronic inflammation in the prostate (84,86,301). These
chronic inflammatory cells generate ROS leading to prostate dysfunction, which in turn
leads to more ROS production (302). Prostate cells try to maintain physiological
homeostasis by the upregulation of intracellular and enzymatic antioxidants to counteract
and regulate the increase in ROS levels during PIA. Signs of stress, such as increase in
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the expression of antioxidants and inflammatory signals (GSTP1, GSTA1, and COX-2)
as well as features of intermediate differentiation between epithelial and columnar cells,
are usually observed in PIA lesions (84,91,303,304). A hallmark in the transition from
PIA to PIN is the loss of GSTP1 function. GSTP1 belongs to the GST family, which are
enzymes that catalyze the conjugation of the chemical scavenger glutathione to various
reactive chemical species. Loss of GSTP1 leads to somatic CpG island hypermethylation
leading to inadequate defenses against dietary and oxidant carcinogenesis (305). Loss of
GSTP1 has been observed in 6.3% of PIA lesions, at least 70% of PIN lesions, and in
90% of PCa (38). These studies support the idea that PIA might be a precursor of PIN
lesions.
One characteristic of PIN lesions is an increased expression of cycloxygenase 2
(COX-2) (306,307). COX-2 is a rate limiting enzyme in prostaglandin biosynthesis that is
induced by inflammatory signals. Overexpression of COX-2 has been shown to be
sufficient to induce breast tumors in transgenic mice and its inhibition leads to the
elimination of breast cancer cell growth and progression (308). In addition, it has been
observed that COX-2 inhibition can induce a significant increase in prostate cell
apoptosis (309). Overexpression of COX-2 in PIN lesions is indicative of an active
inflammatory response in these lesions as well as in PCa, which is consistent with an
environment of increased oxidative stress during the progression of prostate
carcinogenesis (298). Furthermore, the loss of another protein involved in the
maintenance of redox balance in the prostate, the transcription factor erythroid 2p45 (NFE2)-related factor 2 (Nrf-2), has been observed in PCa (310). Nrf-2 mediates the
expression of key protective enzymes through the antioxidant response element (ARE) in
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PCa (310). In response to ROS, the ARE regulates the basal transcription and induction
of antioxidant enzymes (310). Nrf-2 has been shown to regulate antioxidants such as
NAD(P)H:quinone oxidoreductase (NQOl), heme oxygenase, thioredoxin reductase 1,
and glutamate cysteine ligase modifier subunit (311,312). Frohlich et al. were the first to
demonstrate that Nrf2 downregulation in PCa leads to an increase in ROS and DNA
damage (310). These studies show how PCa carcinogenesis is tightly linked to an
inflammatory response which induces an imbalance in the levels of ROS leading to an
oxidative stress environment. In such environment, defects in apoptosis and upregulation
of survival proteins play an important role in tumor initiation, progression and
chemoresistance.

LEDGF/p75 Protects Against Oxidative Stress
As mentioned previously, LEDGF/p75 is a survival protein and transcriptional co
activator upregulated in PCa cell lines and tissues (279). Early studies on LEDGF/p75
uncovered its pro-survival properties in lens epithelial cells (LECs) (207). LECs
overexpressing LEDGF/p75 were shown to be protected against thermal and oxidative
stress (207). LEDGF/p75 overexpressing cells showed upregulation of Hsp27 and aBcrystallin (207). Subsequently, Singh’s group observed stimulated attachment, shortened
length of lag in growth, and enhanced growth rate in LECs and cos-7 cells
overexpressing LEDGF/p75 (237). Also, this overexpression was able to prolong the
survival of LECs in the absence of serum, once again confirming LEDGF/p75’s ability to
protect cells from stress (237). Furthermore, overexpression of LEDGF/p75 in retinal
pigment epithelium (RPE) exerted a protective effect against DNA damage induced by
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H2O2 and UVB and suggested that the mechanism by which the protection occurred was
through the upregulation of Hsp27 by LEDGF/p75 (313). Two different studies from the
same group observed upregulation of heat shock proteins or chaperones by LEDGF/p75
(207,239). To determine whether LEDGF/p75 binds to promoter regions of stress genes,
DNA fragments that bound to LEDGF/p75 were isolated by affinity chromatography and
confirmed using electrophoretic mobility shift assay (EMSA) (244). Consensus
sequences were obtained (nGAAn and nAGGn) and it was found that both heat shock
elements (HSE) and stress response elements (STRE) contain these consensus sequences
(244). Further, RT-PCR analysis indicated that multiple stress-related proteins such as
AOP2/Prdx6, ADH, Hsp27, and aB-crystallin were stimulated by LEDGF/p75. An
important fact is that the promoter region for these proteins contained either HSE or
STRE (244). Fatma et al. (243) observed that LEDGF/p75 can bind to five of the seven
presumptive binding sites in the AOP2/Prdx6 promoter. Sequential mutations in this
promoter were associated with a decrease in AOP2/Prdx6 transactivation (243).
Overexpression of LEDGF/p75 in LECs and cos-7 cells upregulated the
AOP2/Prdx6, and this upregulation protected the cells from H202-induced death (243).
This was confirmed with antisense experiments that showed that AOP2/Prdx6 played a
major role in the cellular defense against oxidative stress (243). Furthermore, Mao et al.
observed that overexpression of Bcl-2 in rabbit LECs attenuated the cell’s ability to
metabolize H2O2 (248). Also, Bcl-2 expression in these cells downregulated aB-crystallin
expression by modifying LEDGF/p75’s binding to the aB-crystallin’s promoter (248).
Furthermore, when Bcl-2 was depleted, aB-crystallin’s expression was restored and the
cell’s regained their ability to metabolize H2O2 (248), thus providing evidence of aB-
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crystallin’s involvement in the protection against oxidative stress (248). Further studies
explored the pathway by which Bcl-2 downregulated aB-crystallin (314). It was shown
that Bcl-2 required the activation of the RAF/MRK/ERK pathway to downregulate
LEDGF/p75 binding activity to the promoter region of aB-crystallin (314). All these
studies pointed LEDGF/p75’s role in protecting cells against stress-induced death
through its ability to transactivate stress response proteins.
Previously, our group showed that overexpression of LEDGF/p75 protected
HepG2 cells from serum starvation-induced death, which has been associated with
increased oxidative stress (222).We were able to show that overexpression of
LEDGF/p75 in the PCa cell line RWPE-2 protected cells against oxidative stress induced
death (induced by tert-butyl hydrogen peroxide, TBHP), but not against classical
apoptosis inducers (TRAIL and staurosporin) (Chapter 3). Stable clones overexpressing
LEDGF/p75 displayed reduced levels of intracellular ROS when compared to the
parental RWPE-2 (Chapter 3). These findings suggested that LEDGF/p75’s ability to
protect PCa cells against oxidative stress-induced death is associated with reduction of
ROS in the cells. This was confirmed by our demonstration that only TBHP-induced cell
death increased the levels of ROS, while no increase was observed during TRAIL and
staurosporine-induced death. These findings are in line with previous studies reporting
LEDGF/p75’s ability to protect against oxidative stress-induced death in non-tumor cell
lines.
In light of LEDGF/p75’s ability to protect cells against stress possibly through the
transactivation of stress proteins, a stress and heat shock protein screen was done to
examine which proteins were upregulated in RWPE-2 cells stably overexpressing
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LEDGF/p75. The analysis showed a dramatic upregulation of the oxidoreductase ERp57,
when compared to RWPE-2 cells stably expressing the empty vector pcDNA3.1+
(Chapter 3). A luciferase based transcription reporter assay showed transactivation of the
ERp57 promoter in cells co-transfected with LEDGF/p75 but not in cells transfected with
the empty vector (Chapter 3). A discrepancy in our studies was the lack of correlation
between LEDGF/p75 and ERp57 expression in a panel of PCa cell lines and tumor
tissues (Chapter 3). Moreover, depletion of LEDGF/p75 in PC3 and RWPE-2 cells did
not lead to decreased levels of ERp57. A possible reason for this discrepancy could be the
fact that LEDGF/p75 is a transcription co-activator and not a transcription factor.
LEDGF/p75 might be one of many transcription proteins that when upregulated by stress
might contribute to the transactivation of ERp57. Depletion of LEDGF/p75 would not
have a major effect in ERp57 expression if other transcription factors are involved in
ERp57 regulation. Even though our data suggests that there is no correlation between
LEDGF/p75 and ERp57 in PCa cell lines further studies should examine the possibility
that LEDGF/p75 may bind directly to ERp57 to modulate its function. It is also possible
that LEDGF/p75 contributes to ERp57 upregulation only under conditions of increased
oxidative stress. In addition, to confirm that ERp57 is part of the mechanism by which
LEDGF/p75 promotes protection against oxidative stress-induced death in PCa cells,
studies should be conducted to determine whether overexpression of ERp57 would also
exert a protective effect against TBHP-induced cell death in PCa cells.
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Cellular Functions of ERp57
ERp57, also known as glucose-regulated protein 58 (Grp58), is a member of the
protein disulfide isomerase (PDI) family, found mainly in the endoplasmic reticulum.
However, it has also been localized in the cytosol and nucleus in lesser amounts (315).
Members of the PDI family contain one or more domains with sequence homology to
thioredoxin. The redox activity of this domain is provided by two cysteine residues in the
sequence motif CXXC (316). ERp57 is a component of the
calnexin(CNX)/calreticulin(CRT) chaperone system that promotes the folding of
glycoproteins in the ER (317). When ERp57 associates with CNX and CRT it acts as a
thiol-disulfide oxidoreductase for proteins with N-linked glycans (318,319). ERp57 is an
important component of the major histocompatibility complex (MHC) class I peptide
loading complex, and participates in the folding of influenza hemagglutinin (320-322). In
the cytosol, ERp57 interacts with the transcription factor STAT3 in HepB2 cells
stimulated with IL-6 as part of the statosome I complex (323). ERp57 has also been
located in the nuclei of rat spermatides and spermatozoa (324).
Chen et al. were able to observe overexpression of ERp57 in lung
adenocarcinomas, when compared to normal lung (325). In addition, it was observed that
ERp57 plays an important role in ovarian cancer chemoresistance to paclitaxel-induced
death (326). However, in gastric cells, loss of ERp57 expression correlates with a more
aggressive disease (327).
Recently, ERp57 was shown by Grillo et al. to bind to Ref-1, a protein involved in
DNA repair (296). These investigators reported that Ref-1 protected against ROS. They
also showed that overexpression of ERp57 in HeLa cells had a protective effect against
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ROS (296). These studies emphasized the importance of ERp57/Ref-l in the response to
oxidative stress. Corazzari et al. showed that depletion of ERp57 sensitized cells to
fenretinide and velcade (328). Fenretinide is a retinoid analog that induces apoptosis
associated with generation of ROS. Velcade is a new anti-cancer drug that induces ERstress responses in some cell types, apparently mediated by ROS induction (329).
However, velcade was ineffective at inducing ROS in SH-SY5Y human neuroblastoma
cell line (328). The exact mechanism by which ERp57 depletion sensitized cells to these
drugs is not fully understood but it can be speculated that ERp57 absence leaves cells
vulnerable to drugs that induce ROS. These studies provide evidence that might support
our work, establishing that ERp57 might be involved in the attenuation of oxidative
stress-induced death through the reduction in the cellular levels of ROS. Although the
evidence might point in that direction, further studies are needed to fully elucidate
ERp57’s function in resistance to chemotherapeutic drugs that induce ROS.

DTX in HRPC
As mentioned previously, DTX is the first line treatment for patients with HRPC
since it confers a survival advantage. The only limitation of this treatment is that with
time the tumors recur and become resistant to DTX. Studies aimed at circumventing the
underlying resistance to DTX have focused on the difference in expression of f3-tubulin
isoforms, expression of Pgp/MDRl, and the loss the apoptotic machinery (330,331). For
this reason, a better understanding of mechanistic events associated with DTX-induced
cel death in PCa is needed to develop more comprehensive and efficient targeted therapy.
Until recently, the mechanism by which DTX induces death in PCa cells has been
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described as mitotic catastrophe followed by the activation of the apoptotic pathway.
Most of the undergoing studies on DTX chemoresistance are focused on proteins
involved in these cell deaths.
We have established that DTX not only induces mitotic catastrophe and apoptosis,
but also activates a caspase-independent lysosomal cell death pathway in PCa cells. We
observed that HRPC cells (PCS, DU 145 and RWPE-2) treated with low and high doses of
DTX (0.1 pM and 3.0 pM) display both apoptotic and non-apoptotic characteristics
(Chapter 2). We were able to show that during permeabilization of the lysosomes
following DTX treatment, cathepsin B is activated and play a role in DTX-induced cell
death (Chapter 2). In addition, when both caspases and cathepsin B were inhibited, HRPC
cells exhibited reduced DNA fragmentation and regained lysosomal stability (Chapter 2).
These studies provided evidence that both the caspase-dependent and -independent
pathways are activated by DTX in PCa cells and that inhibition of both pathways might
lead to better chemotherapeutic strategies against resistance to the drug.
Identifying survival proteins that protect against both the lysosomal and apoptotic
pathways could be very relevant for designing targeted therapies that could be used in
combination with DTX. One such survival protein could be LEDGF/p75. LEDGF/p75’s
involvement in lysosomal stabilization was first hinted by Daugaard et al. (280) who
observed that overexpression of the protein led to lysosomal stabilization after treatment
with drugs that targeted the lysosomes. In addition, siRNA studies were performed and
showed that transient depletion of LEDGF/p75 in HeLa cells led to a decrease in cell
viability (280). We examined the possibility that LEDGF/p75 might be involved in DTX
resistance, given that DTX induces lysosomal destabilization, and observed that stable
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overexpression of LEDGF/p75 in PC3 cells attenuated cell death induced by low and
high doses of DTX (Chapter 2). In addition, decreased DNA fragmentation and increased
lysosomal stability were observed when compared to PC3 cells stably transfected with
empty vector. LEDGF/p75’s protective effect is likely related to its ability to stabilize the
lysosomes during DTX-induced cell death. Our data suggest that DTX-induced death in
PC3 cells is associated with increased levels of ROS, which could be consistent with
previous observations in HL-60, HepG2, and SMMC-7721 cells (332-335). It is well
established that increased ROS destabilizes lysosomal membranes, leading to their
leakage, cathepsin activation, and cell death (336-338). Thus, it is very likely that
LEDGF/p75 protects PC3 cells from DTX-induced death via transactivation of stress
genes, such as ERp57, that reduce the intracellular levels of ROS, thereby preventing
lysosomal disruption (Figure 25). Further studies are needed to better understand whether
the protective effect that LEDGF/p75 exerts in cells treated with ROS-generating drugs
such as DTX is associated with its ability to decrease of intracellular levels of ROS.
Some experiments might include the inhibition of ROS by known antioxidants to
determine if this inhibition leads to stabilized lysosomes and protection against DTXinduced death. It would also be of interest to determine whether LEDGF/p75 knockdown
increases ROS or renders cells sensitive to low concentrations of TBHP or DTX.
We observed that knockdown of LEDGF/p75 in PC3 cells did not decrease cell
viability, in contrast to Daugaard’s studies which showed that LEDGF/p75 knockdown
did in fact decrease HeLa cell’s viability (Chapter 4 and (280)). In addition, we decided
to treat PC3 cells with a relative low dose of DTX (0.1 pM) to observe if under stress
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Figure 25. Proposed mechanism by which LEDGF/p75 protects PCa cells. We propose
that LEDGF/p75 decreases the intracellular levels of ROS in PCa cells thus providing an
increased survival potential.
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conditions we would be able to observe sensitization to DTX. Our data suggests that
knockdown of LEDGF/p75 does not sensitize PC3 cells to low concentrations of DTX
(Chapter 4). A possible explanation for these discrepancies might be differences in the
transfection protocols or choice of siRNAsused by our group and Daugaard et al (280).
Experiments are underway to compare transfection techniques and siRNA oligos and
observe if these were causing the contrasting results.
To observe if LEDGF/p75 or ERp57 were important components in the
chemoresistant phenotype of HRPC cells we decided to study the effects of their
depletion on cellular sensitivity to DTX. We observed in preliminary studies that in PC3
cells transiently depleted of LEDGF/p75 or ERp57 there was no sensitization against low
or high concentrations of DTX (Chapter 4). Future studies should test if lower
concentrations of the drug might be needed to observe any sensitization against DTX.
Although these preliminary results suggest at first glance that LEDGF/p75 and ERp57
may not play important roles in chemoresistance, additional experiments are needed to
carefully examine this issue. Even though no sensitization was observed in vitro under
conditions where cells were growing in monolayer in the presence of medium
supplemented with serum, we can not rule out that in semi-solid media or in vivo animal
model we could observe the complete opposite effect. These differences might be due to
the fact that in vivo the environment its stressed (low nutrient, low oxygen) while in an in
vitro model, unless specified, the environment is full of nutrients and normal levels of
oxygen.
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Conclusions and Future Perspectives
The studies presented here showed that DTX induced PCa cell death involved the
concomitant activation of caspase and lysosomal pathways and that overexpression of the
stress survival protein LEDGF/p75 attenuated DTX-induced lysosomal destabilization
and cell death. LEDGF/p75-mediated attenuation of DTX-induced cell death was
selective since cell death induced by TRAIL or STS was not affected. This was probably
due to LEDGF/p75’s ability to decrease intracellular levels of damaging ROS produced
by DTX. We showed that DTX induced the generation of ROS in PCa cells, and
experiments are underway to determine if LEDGF/p75 overexpression or depletion
influence the intracellular levels of ROS in PCa cells exposed to low and high doses of
DTX. In addition, LEDGF/p75 selectively protected against TBHP-induced cell death
and decreased the levels of intracellular ROS in PCa cells. This probably occurred
through the transactivation of stress or redox proteins such as the oxidoreductase ERp57.
These studies strongly suggest that LEDGF/p75, through its transactivation of stress
proteins (ERp57, Hsp27, AOP2/Prdx6), might elicit selective protection against
chemotherapy and oxidative stress-induced death by reducing intracellular ROS. Further
studies should explore more in detail whether LEDGF/p75 and ERp57 play a key role in
DTX resistance through modulation of intracellular ROS. For instance, stable PC3 clones
overexpressing LEDGF/p75 or ERp57 could be injected sub-cutaneous (s.c.) in mouse
models to observe if tumors are resistant to DTX-induced death, or the opposite, if
clones with stable LEDGF/p75 or ERp57 knockdown sensitize tumors to DTX-induced
death. These studies could provide a rationale for developing novel therapeutic strategies
aimed at targeting these proteins during treatment of HRPC with DTX.
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